10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended
	March 31, 2023
	or
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from __________ to __________

Commission File Number: 001-35797

Zoetis Inc.

(Exact name of registrant as specified in its charter)

 

Delaware			46-0696167
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
10 Sylvan Way,	Parsippany,	New Jersey	07054
(Address of principal executive offices)			(Zip Code)

(973) 822-7000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ZTS	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of April 28, 2023, there were 462,112,140 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
PART I — FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
	Condensed Consolidated Statements of Income (Unaudited)	1
	Condensed Consolidated Statements of Comprehensive Income (Unaudited)	2
	Condensed Consolidated Balance Sheets (Unaudited)	3
	Condensed Consolidated Statements of Equity (Unaudited)	4
	Condensed Consolidated Statements of Cash Flows (Unaudited)	5
	Notes to Condensed Consolidated Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35
PART II — OTHER INFORMATION		36
Item 1.	Legal Proceedings	36
Item 1A.	Risk Factors	36
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3.	Defaults Upon Senior Securities	36
Item 4.	Mine Safety Disclosures	36
Item 5.	Other Information	36
Item 6.	Exhibits	36
SIGNATURES		37

PART I – FINANCIAL INFORMATION

Item 1.    Financial Statements

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2023		2022
Revenue	$	2,000	$	1,986
Costs and expenses:
Cost of sales	588		569
Selling, general and administrative expenses	505		465
Research and development expenses	142		122
Amortization of intangible assets	37		41
Restructuring charges and certain acquisition-related costs	21		2
Interest expense, net of capitalized interest	63		53
Other (income)/deductions—net	(53)		7
Income before provision for taxes on income	697		727
Provision for taxes on income	146		133
Net income before allocation to noncontrolling interests	551		594
Less: Net loss attributable to noncontrolling interests	(1)		(1)
Net income attributable to Zoetis Inc.	$	552	$	595
Earnings per share attributable to Zoetis Inc. stockholders:
Basic	$	1.19	$	1.26
Diluted	$	1.19	$	1.26
Weighted-average common shares outstanding:
Basic	463.5		472.2
Diluted	464.6		474.1
Dividends declared per common share	$	0.375	$	0.325

See notes to condensed consolidated financial statements.

1 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Net income before allocation to noncontrolling interests	$	551	$	594
Other comprehensive (loss)/income, net of tax(a):
Unrealized (losses)/gains on derivatives for cash flow hedges, net of tax of $(1) and $7 for the three months ended March 31, 2023 and 2022, respectively	(2)		26
Unrealized (losses)/gains on derivatives for net investment hedges, net of tax of $(2) and $4 for the three months ended March 31, 2023 and 2022, respectively	(6)		12
Foreign currency translation adjustments	(7)		21
Benefit plans: Actuarial gain, net of tax of $1 and $0 for the three months ended March 31, 2023 and 2022, respectively	4		1
Total other comprehensive (loss)/income, net of tax	(11)		60
Comprehensive income before allocation to noncontrolling interests	540		654
Less: Comprehensive loss attributable to noncontrolling interests	(1)		(1)
Comprehensive income attributable to Zoetis Inc.	$	541	$	655

(a) Presented net of reclassification adjustments, which are not material in any period presented.

See notes to condensed consolidated financial statements.

2 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
	2023		2022
(MILLIONS OF DOLLARS, EXCEPT SHARE AND PER SHARE DATA)	(Unaudited)
Assets
Cash and cash equivalents(a)	$	2,109	$	3,581
Accounts receivable, less allowance for doubtful accounts of $20 in 2023 and $19 in 2022	1,186		1,215
Inventories	2,563		2,345
Other current assets	411		365
Total current assets	6,269		7,506
Property, plant and equipment, less accumulated depreciation of $2,374 in 2023 and $2,297 in 2022	2,913		2,753
Operating lease right of use assets	216		220
Goodwill	2,738		2,746
Identifiable intangible assets, less accumulated amortization	1,314		1,380
Noncurrent deferred tax assets	161		173
Other noncurrent assets	143		147
Total assets	$	13,754	$	14,925
Liabilities and Equity
Short-term borrowings	$	3	$	2
Current portion of long-term debt	—		1,350
Accounts payable	424		405
Dividends payable	174		174
Accrued expenses	701		682
Accrued compensation and related items	232		300
Income taxes payable	277		157
Other current liabilities	104		97
Total current liabilities	1,915		3,167
Long-term debt, net of discount and issuance costs	6,559		6,552
Noncurrent deferred tax liabilities	131		142
Operating lease liabilities	180		186
Other taxes payable	262		258
Other noncurrent liabilities	216		217
Total liabilities	9,263		10,522
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 462,495,343 and 463,808,059 shares outstanding at March 31, 2023, and December 31, 2022, respectively	5		5
Treasury stock, at cost, 39,395,900 and 38,083,184 shares of common stock at March 31, 2023 and December 31, 2022, respectively	(4,807)		(4,539)
Additional paid-in capital	1,079		1,088
Retained earnings	9,045		8,668
Accumulated other comprehensive loss	(828)		(817)
Total Zoetis Inc. equity	4,494		4,405
Noncontrolling interests	(3)		(2)
Total equity	4,491		4,403
Total liabilities and equity	$	13,754	$	14,925

(a)    As of March 31, 2023 and December 31, 2022, includes $4 million of restricted cash.

See notes to condensed consolidated financial statements.

3 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

Three months ended March 31, 2023
	Zoetis
												Accumulated
								Additional				Other
		Common Stock			Treasury Stock			Paid-in		Retained		Comprehensive		Noncontrolling		Total
(MILLIONS OF DOLLARS AND SHARES)		Shares	Amount		Shares	Amount		Capital		Earnings		Loss		Interests		Equity
Balance, December 31, 2022		501.9	$	5	38.1	$	(4,539)	$	1,088	$	8,668	$	(817)	$	(2)	$	4,403
Net income/(loss)		—	—		—	—		—		552		—		(1)		551
Other comprehensive loss		—	—		—	—		—		—		(11)		—		(11)
Share-based compensation awards (a)		—	—		(0.4)	17		(9)		(1)		—		—		7
Treasury stock acquired (b)		—	—		1.7	(285)		—		—		—		—		(285)
Dividends declared		—	—		—	—		—		(174)		—		—		(174)
Balance, March 31, 2023		501.9	$	5	39.4	$	(4,807)	$	1,079	$	9,045	$	(828)	$	(3)	$	4,491
Three months ended March 31, 2022
	Zoetis
												Accumulated
								Additional				Other
		Common Stock			Treasury Stock			Paid-in		Retained		Comprehensive		Noncontrolling		Total
(MILLIONS OF DOLLARS AND SHARES)		Shares	Amount		Shares	Amount		Capital		Earnings		Loss		Interests		Equity
Balance, December 31, 2021		501.9	$	5	29.3	$	(2,952)	$	1,068	$	7,186	$	(764)	$	1	$	4,544
Net income/(loss)		—	—		—	—		—		595		—		(1)		594
Other comprehensive income		—	—		—	—		—		—		60		—		60
Share-based compensation awards (a)		—	—		(0.5)	(4)		(23)		—		—		—		(27)
Treasury stock acquired (b)		—	—		1.9	(361)		—		—		—		—		(361)
Employee benefit plan contribution from Pfizer Inc.(c)		—	—		—	—		1		—		—		—		1
Dividends declared		—	—		—	—		—		(153)		—		—		(153)
Balance, March 31, 2022		501.9	$	5	30.7	$	(3,317)	$	1,046	$	7,628	$	(704)	$	—	$	4,658

Shares may not add due to rounding.

(a)    Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders' Equity.

(b)    Reflects the acquisition of treasury shares in connection with the share repurchase program. For the three months ended March 31, 2023, includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders' Equity.

(c)    Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.

See notes to condensed consolidated financial statements.

4 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Operating Activities
Net income before allocation to noncontrolling interests	$	551	$	594
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization expense	120		114
Share-based compensation expense	9		16
Asset write-offs and asset impairments	1		1
Provision for losses on inventory	16		9
Deferred taxes	8		(45)
Employee benefit plan contribution from Pfizer Inc.	—		1
Other non-cash adjustments	(1)		4
Other changes in assets and liabilities, net of acquisitions and divestitures:
Accounts receivable	27		(102)
Inventories	(235)		(146)
Other assets	(24)		(1)
Accounts payable	22		(31)
Other liabilities	(63)		(222)
Other tax accounts, net	118		117
Net cash provided by operating activities	549		309
Investing Activities
Capital expenditures	(223)		(115)
Acquisitions	(7)		(4)
Purchase of investments	(1)		(5)
Proceeds on derivative instrument activity, net	13		6
Net proceeds from sale of assets	2		—
Net cash used in investing activities	(216)		(118)
Financing Activities
Increase in short-term borrowings, net	1		—
Principal payments on long-term debt	(1,350)		—
Share-based compensation-related proceeds, net of taxes paid on withholding shares	4		(30)
Purchases of treasury stock	(283)		(361)
Cash dividends paid	(174)		(154)
Net cash used in financing activities	(1,802)		(545)
Effect of exchange-rate changes on cash and cash equivalents	(3)		4
Net decrease in cash and cash equivalents	(1,472)		(350)
Cash and cash equivalents at beginning of period	3,581		3,485
Cash and cash equivalents at end of period	$	2,109	$	3,135
Supplemental cash flow information
Cash paid during the period for:
Income taxes	$	20	$	26
Interest, net of capitalized interest	89		89
Amounts included in the measurement of lease liabilities	14		13
Non-cash transactions:
Capital expenditures	3		4
Excise tax accrued on net share repurchases, not paid	2		—
Lease obligations obtained in exchange for right-of-use assets	13		19
Dividends declared, not paid	174		153

See notes to condensed consolidated financial statements.

5 |

ZOETIS INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Organization

Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. We organize and operate our business in two geographic regions: the United States (U.S.) and International.

We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, other pharmaceutical products, dermatology, anti-infectives, medicated feed additives and animal health diagnostics.

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three months ended February 28, 2023 and February 28, 2022.

Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2022 Annual Report on Form 10-K.

3. Accounting Standards

Recently Adopted Accounting Standards

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. In January 2021 and December 2022, it issued subsequent amendments to the initial guidance: ASU No. 2021-01 and ASU No. 2022-06, Reference Rate Reform (Topic 848). The new guidance provides temporary optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. Adoption of the guidance is optional and effective as of March 12, 2020, but only available through December 31, 2024. During the first quarter of 2023, we adopted the guidance by executing amendments to our affected contracts that referenced LIBOR. The adoption did not have a material impact on our condensed consolidated financial statements or related disclosures.

4. Revenue

A. Revenue from Product Sales

We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers or e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top-selling product lines are distributed across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.

Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock within each of our major product categories.

Our major product categories are:

•parasiticides: products that prevent or eliminate external and internal parasites such as fleas, ticks and worms;

•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;

•other pharmaceutical products: pain and sedation, antiemetic, reproductive, and oncology products;

•dermatology products: products that relieve itch associated with allergic conditions and atopic dermatitis;

•anti-infectives: products that prevent, kill or slow the growth of bacteria, fungi or protozoa;

•animal health diagnostics: testing and analysis of blood, urine and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services and blood glucose monitors; and

6 |

•medicated feed additives: products added to animal feed that provide medicines to livestock.

Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals, as well as products and services in biodevices, genetic tests and precision animal health.

Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, deepening the human-animal bond, receiving increased medical treatment and benefiting from advances in animal health medicine, vaccines and diagnostics.

Our livestock products primarily help prevent or treat diseases and conditions to allow veterinarians and producers to care for their animals and to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive demand for improved nutrition, particularly through increased consumption of animal protein. Second, population growth leads to greater natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve and the global food chain faces increased scrutiny, there is more focus on food quality, safety and reliability of supply.

The following tables present our revenue disaggregated by geographic area, species and major product category:

Revenue by geographic area

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
United States	$	1,005	$	1,020
Australia	82		65
Brazil	84		77
Canada	50		49
Chile	39		41
China	102		103
France	34		32
Germany	45		43
Italy	26		30
Japan	39		59
Mexico	39		35
Spain	33		33
United Kingdom	68		64
Other developed markets	122		115
Other emerging markets	215		202
	1,983		1,968
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

7 |

Revenue by major species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
U.S.
Companion animal	$	721	$	774
Livestock	284		246
	1,005		1,020
International
Companion animal	504		489
Livestock	474		459
	978		948
Total
Companion animal	1,225		1,263
Livestock	758		705
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue by species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Companion Animal:
Dogs and Cats	$	1,153	$	1,199
Horses	72		64
	1,225		1,263
Livestock:
Cattle	399		364
Swine	142		154
Poultry	139		124
Fish	49		44
Sheep and other	29		19
	758		705
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue by major product category

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Parasiticides	$	432	$	459
Vaccines	429		405
Other pharmaceuticals	294		254
Dermatology	292		311
Anti-infectives	288		285
Animal health diagnostics	93		98
Medicated feed additives	87		98
Other non-pharmaceuticals	68		58
	1,983		1,968
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

B. Revenue from Contracts with Customers

Contract liabilities reflected within Other current liabilities as of December 31, 2022 and 2021, and subsequently recognized as revenue during the first three months of 2023 and 2022 were $1 million and $2 million, respectively. Contract liabilities as of March 31, 2023 and December 31, 2022 were $14 million.

Estimated future revenue expected to be generated from long-term contracts with unsatisfied performance obligations as of March 31, 2023 is not material.

8 |

5. Acquisitions

In 2022, we completed the acquisition of Basepaws, a privately held petcare genetics company based in the U.S., which provides pet owners with genetic tests, analytics and early health risk assessments that can help manage the health, wellness and quality of care for their pets. We also completed the acquisition of NewMetrica, a privately held company based in Scotland, that provides scientifically-developed instruments to measure quality of life in companion animals. These transactions did not have a material impact on our condensed consolidated financial statements.

During 2021, we entered into an agreement to acquire Jurox, a privately held animal health company based in Australia, which develops, manufactures and markets a wide range of veterinary medicines for treating companion animals and livestock. On September 30, 2022, after satisfying all customary closing conditions, including clearance from the Australian Competition and Consumer Commission, we completed the acquisition of Jurox. We acquired 100% of the outstanding shares for an aggregate cash purchase price of $226 million, which was adjusted to $240 million for cash and working capital and other adjustments as of the closing date. Net cash consideration transferred to the seller was $215 million during 2022 and $5 million for the three months ended March 31, 2023. The transaction was accounted for as a business combination, with the assets acquired and liabilities assumed measured at their respective acquisition date fair values. The table below presents the preliminary fair values allocated to the assets and liabilities of Jurox as of the acquisition date:

(MILLIONS OF DOLLARS)	Amounts
Cash and cash equivalents	$	20
Accounts receivable	8
Inventories(a)	21
Other current assets	1
Property, plant and equipment(b)	25
Identifiable intangible assets(c)	135
Other noncurrent assets	1
Accounts payable	2
Other current liabilities	12
Total net assets acquired	197
Goodwill(d)	43
Total consideration	$	240

(a)        Acquired inventory is comprised of finished goods, work in process and raw materials. The fair value of finished goods was determined based on net realizable value adjusted for the costs of the selling effort, a reasonable profit allowance for the selling effort, and estimated holding costs. The fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the selling effort, a reasonable profit allowance for the remaining manufacturing and selling effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value.

(b)    Property, plant and equipment is comprised of buildings, machinery and equipment, land, construction in progress and furniture and fixtures. The fair value was primarily determined using a reproduction/replacement cost approach which measures the value of an asset by estimating the cost to acquire or construct comparable assets adjusted for age and condition of the asset.

(c)    Identifiable intangible assets consist of developed technology rights. The fair value of identifiable intangible assets was determined using the income approach, which includes a forecast of expected future cash flows. For additional information regarding identifiable intangible assets, see Note 11. Goodwill and Other Intangible Assets.

(d)        Goodwill represents the excess of consideration transferred over the fair values of the assets acquired and liabilities assumed. It is allocated to our International segment and is primarily attributable to cost and revenue synergies including market share capture, elimination of cost redundancies and gain of cost efficiencies, and intangible assets such as assembled workforce which are not separately recognizable. The primary strategic purpose of the acquisition was to enhance the company’s existing product portfolio.

All amounts recorded are subject to final valuation. Any adjustments to our preliminary purchase price allocation identified during the measurement period, which will not exceed one year from the acquisition date, will be accounted for prospectively.

6. Restructuring Charges and Other Costs Associated with Acquisitions, Cost-Reduction and Productivity
Initiatives

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. In connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as functions such as business technology, shared services and corporate operations.

9 |

The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Restructuring charges and certain acquisition-related costs:
Integration costs(a)	$	1	$	2
Restructuring charges(b):
Employee termination costs	20		—
Total Restructuring charges and certain acquisition-related costs	$	21	$	2

(a)    Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

(b)    The restructuring charges for the three months ended March 31, 2023 primarily consisted of employee termination costs related to organizational structure refinements.

(MILLIONS OF DOLLARS)	Accrual
Balance, December 31, 2022(a)	$	15
Provision	20
Utilization and other(b)	(3)
Balance, March 31, 2023(a)	$	32

(a)     At March 31, 2023 and December 31, 2022, included in Accrued expenses ($22 million and $5 million, respectively) and Other noncurrent liabilities ($10 million).

(b)     Includes adjustments for foreign currency translation.

7. Other (Income)/Deductions—Net

The components of Other (income)/deductions—net are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Royalty-related income(a)	$	(34)	$	(1)
Interest income	(33)		(2)
Foreign currency loss(b)	9		11
Other, net	5		(1)
Other (income)/deductions—net	$	(53)	$	7

(a)     For the three months ended March 31, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.

(b)     Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.

8. Income Taxes

A. Taxes on Income

Our effective tax rate was 20.9% for the three months ended March 31, 2023, compared with 18.3% for the three months ended March 31, 2022. The higher effective tax rate for the three months ended March 31, 2023, was attributable to lower net discrete tax benefits for the three months ended March 31, 2023 and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income for the three months ended March 31, 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.

In 2022, the company implemented an initiative to maximize its cash position in the U.S. This initiative resulted in a tax benefit in the U.S. in connection with a prepayment from a related foreign entity in Belgium which qualifies as foreign-derived intangible income; however, this income tax benefit was deferred for 2022. A portion of this benefit was recognized during the three months ended March 31, 2023.

B. Deferred Taxes

As of March 31, 2023, the total net deferred income tax asset of $30 million is included in Noncurrent deferred tax assets ($161 million) and Noncurrent deferred tax liabilities ($131 million).

As of December 31, 2022, the total net deferred income tax asset of $31 million is included in Noncurrent deferred tax assets ($173 million) and Noncurrent deferred tax liabilities ($142 million).

10 |

C. Tax Contingencies

As of March 31, 2023, the net tax liabilities associated with uncertain tax positions of $196 million (exclusive of interest and penalties related to uncertain tax positions of $21 million) are included in Noncurrent deferred tax assets and Other noncurrent assets ($1 million) and Other taxes payable ($195 million).

As of December 31, 2022, the net tax liabilities associated with uncertain tax positions of $194 million (exclusive of interest and penalties related to uncertain tax positions of $19 million) are included in Noncurrent deferred tax assets and Other noncurrent assets ($2 million) and Other taxes payable ($192 million).

Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

9. Financial Instruments

A. Debt

Credit Facilities

In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. The credit facility replaced the company's existing revolving credit facility dated as of December 2016. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.

We were in compliance with all financial covenants as of March 31, 2023 and December 31, 2022. There were no amounts drawn under the credit facility as of March 31, 2023 or December 31, 2022.

We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of March 31, 2023, we had access to $51 million of lines of credit which expire at various times and are generally renewed annually. There were $3 million of borrowings outstanding related to these facilities as of March 31, 2023 and $2 million of borrowings outstanding related to these facilities as of December 31, 2022.

Commercial Paper Program

In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of March 31, 2023 and December 31, 2022, there was no commercial paper outstanding under this program.

Senior Notes and Other Long-Term Debt

On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.

Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

11 |

The components of our long-term debt are as follows:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
3.250% 2013 senior notes due 2023	$	—	$	1,350
4.500% 2015 senior notes due 2025	750		750
5.400% 2022 senior notes due 2025	600		600
3.000% 2017 senior notes due 2027	750		750
3.900% 2018 senior notes due 2028	500		500
2.000% 2020 senior notes due 2030	750		750
5.600% 2022 senior notes due 2032	750		750
4.700% 2013 senior notes due 2043	1,150		1,150
3.950% 2017 senior notes due 2047	500		500
4.450% 2018 senior notes due 2048	400		400
3.000% 2020 senior notes due 2050	500		500
	6,650		8,000
Unamortized debt discount / debt issuance costs	(65)		(66)
Less current portion of long-term debt	—		1,350
Cumulative fair value adjustment for interest rate swap contracts	(26)		(32)
Long-term debt, net of discount and issuance costs	$	6,559	$	6,552

The fair value of our long-term debt was $6,273 million and $6,108 million as of March 31, 2023 and December 31, 2022, respectively, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from, or corroborated by, observable market data and Zoetis’ credit rating (Level 2 inputs).

The principal amount of long-term debt outstanding, as of March 31, 2023, matures in the following years:

											After
(MILLIONS OF DOLLARS)	2023		2024		2025		2026		2027		2027		Total
Maturities	$	—	$	—	$	1,350	$	—	$	750	$	4,550	$	6,650

Interest Expense

Interest expense, net of capitalized interest, was $63 million and $53 million for the three months ended March 31, 2023 and 2022, respectively. Capitalized interest expense was $6 million and $5 million for the three months ended March 31, 2023 and 2022, respectively.

B. Derivative Financial Instruments

Foreign Exchange Risk

A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.

All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the Condensed Consolidated Balance Sheets. The derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Chinese yuan, euro, Japanese yen and Norwegian krone. Changes in fair value are reported in earnings or in Accumulated other comprehensive income/(loss), depending on the nature and purpose of the financial instrument, as follows:

•For foreign currency forward-exchange contracts not designated as hedging instruments, we recognize the gains and losses that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The vast majority of the foreign currency forward-exchange contracts mature within 60 days and all mature within three years.

•For foreign exchange derivative instruments that are designated as hedging instruments against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within Accumulated other comprehensive income/(loss) and reclassified into earnings when the foreign investment is sold or substantially liquidated. These instruments include cross-currency interest rate swaps and foreign currency forward-exchange contracts. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (Interest expense, net of capitalized interest). The cash flows from these contracts are reflected within the investing section of our Condensed Consolidated Statements of Cash Flows. These contracts have varying maturities of up to three years.

Interest Rate Risk

The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing.

12 |

•In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in Accumulated other comprehensive loss and are recognized in earnings over the life of the future fixed rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.

•During the period from 2019 to 2022, we entered into forward-starting interest rate swaps with an aggregate notional value of $650 million. We designated these swaps as cash flow hedges against interest rate exposure related principally to the issuance of fixed-rate debt to refinance our 3.250% 2013 senior notes due 2023. Upon issuance of our 2022 senior notes, we terminated these contracts and received $114 million in cash from the counterparties for settlement, included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows. The settlement amount, which represented the fair value of the contracts at the time of termination, was recorded in Accumulated other comprehensive loss, and will be amortized into income (offset to Interest expense, net of capitalized interest) over the life of the 5.600% 2022 senior notes due 2032.

•As of March 31, 2023, we had outstanding a forward-starting interest rate swap, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500% 2015 senior notes due 2025.

•We may use fixed-to-floating interest rate swaps that are designated as fair value hedges to hedge against changes in the fair value of certain fixed-rate debt attributable to changes in the benchmark the Secured Overnight Financing Rate (SOFR). These derivative instruments effectively convert a portion of the company’s long-term debt from fixed-rate to floating-rate debt based on the daily SOFR rate plus a spread. Gains or losses on the fixed-to-floating interest rate swaps due to changes in SOFR are recorded in Interest expense, net of capitalized interest. Changes in the fair value of the fixed-to-floating interest rate swaps are offset by changes in the fair value of the underlying fixed-rate debt. As of March 31, 2023, we had outstanding fixed-to-floating interest rate swaps that correspond to a portion of the 3.900% 2018 senior notes due 2028 and the 2.000% senior notes due 2030. The amounts recorded during the three months ended March 31, 2023 for changes in the fair value of these hedges are not material to our condensed consolidated financial statements.

During the first quarter of 2023, we executed amendments to certain of our interest rate swap contracts, which changed the floating rate index from LIBOR to SOFR. These amendments did not have a material impact on our condensed consolidated financial statements.

Outstanding Positions

The aggregate notional amount of derivative instruments are as follows:

	Notional
	March 31,		December 31,
(MILLIONS)	2023		2022
Derivatives not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	$	1,716	$	1,753
Derivatives Designated as Hedging Instruments
Foreign exchange derivative instruments (in foreign currency):
Euro	650		650
Danish krone	600		600
Swiss franc	25		25
Forward-starting interest rate swaps	$	50	$	50
Fixed-to-floating interest rate swap contracts	$	250	$	250

13 |

Fair Value of Derivative Instruments

The classification and fair values of derivative instruments are as follows:

		Fair Value of Derivatives
		March 31,		December 31,
(MILLIONS OF DOLLARS)	Balance Sheet Location	2023		2022
Derivatives Not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	Other current assets	$	16	$	22
Foreign currency forward-exchange contracts	Other current liabilities	(15)		(21)
Total derivatives not designated as hedging instruments		$	1	$	1
Derivatives Designated as Hedging Instruments:
Forward-starting interest rate swap contracts	Other noncurrent assets	$	9	$	10
Foreign exchange derivative instruments	Other current assets	11		21
Foreign exchange derivative instruments	Other noncurrent assets	17		19
Foreign exchange derivative instruments	Other current liabilities	(14)		(9)
Foreign exchange derivative instruments	Other noncurrent liabilities	(6)		(4)
Fixed-to-floating interest rate swap contracts	Other noncurrent liabilities	(26)		(32)
Total derivatives designated as hedging instruments		(9)		5
Total derivatives		$	(8)	$	6

The company’s derivative transactions are subject to master netting agreements that mitigate credit risk by permitting net settlement of transactions with the same counterparty. The company also has collateral security agreements with certain of its counterparties. Under these collateral security agreements either party is required to post cash collateral when the net fair value of derivative instruments covered by the collateral agreement exceeds contractually established thresholds. At March 31, 2023, there was $6 million of collateral received and $21 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively. At December 31, 2022, there was $8 million of collateral received and $21 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively.

We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.

The amounts of net losses on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Foreign currency forward-exchange contracts	$	(16)	$	(6)

These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.

The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Forward-starting interest rate swap contracts	$	(1)	$	26
Foreign exchange derivative instruments	$	(6)	$	12

Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Foreign exchange derivative instruments	$	5	$	3

The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from Accumulated other comprehensive loss into earnings over the next 12 months is not material.

14 |

10. Inventories

The components of inventory are as follows:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
Finished goods	$	1,065	$	1,090
Work-in-process	999		825
Raw materials and supplies	499		430
Inventories	$	2,563	$	2,345

11. Goodwill and Other Intangible Assets

A. Goodwill

The components of, and changes in, the carrying amount of goodwill are as follows:

(MILLIONS OF DOLLARS)	U.S.		International		Total
Balance, December 31, 2022	$	1,485	$	1,261	$	2,746
Adjustments	—		(1)		(1)
Other(a)	—		(7)		(7)
Balance, March 31, 2023	$	1,485	$	1,253	$	2,738

(a) Includes adjustments for foreign currency translation.

The gross goodwill balance was $3,274 million and $3,282 million as of March 31, 2023 and December 31, 2022, respectively. Accumulated goodwill impairment losses (generated entirely in fiscal 2002) were $536 million as of March 31, 2023 and December 31, 2022.

B. Other Intangible Assets

The components of identifiable intangible assets are as follows:

	As of March 31, 2023						As of December 31, 2022
					Identifiable						Identifiable
	Gross				Intangible Assets		Gross				Intangible Assets
	Carrying		Accumulated		Less Accumulated		Carrying		Accumulated		Less Accumulated
(MILLIONS OF DOLLARS)	Amount		Amortization		Amortization		Amount		Amortization		Amortization
Finite-lived intangible assets:
Developed technology rights	$	1,900	$	(1,006)	$	894	$	1,918	$	(975)	$	943
Brands and tradenames	390		(239)		151		395		(237)		158
Other	332		(238)		94		337		(233)		104
Total finite-lived intangible assets	2,622		(1,483)		1,139		2,650		(1,445)		1,205
Indefinite-lived intangible assets:
Brands and tradenames	91		—		91		91		—		91
In-process research and development	77		—		77		77		—		77
Product rights	7		—		7		7		—		7
Total indefinite-lived intangible assets	175		—		175		175		—		175
Identifiable intangible assets	$	2,797	$	(1,483)	$	1,314	$	2,825	$	(1,445)	$	1,380

C. Amortization

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $47 million and $52 million for the three months ended March 31, 2023 and 2022, respectively.

12. Share-based Payments

The Zoetis 2013 Equity and Incentive Plan (Equity Plan) provides long-term incentives to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards.

15 |

The components of share-based compensation expense are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Stock options / stock appreciation rights	$	1	$	2
RSUs / DSUs	7		9
PSUs	1		5
Share-based compensation expense—total(a)	$	9	$	16

(a) For the three months ended March 31, 2023 and 2022, we capitalized less than $1 million of share-based compensation expense to inventory.

During the three months ended March 31, 2023, the company granted 268,008 stock options with a weighted-average exercise price of $162.07 per stock option and a weighted-average fair value of $43.56 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 3.84%; expected dividend yield of 0.92%; expected stock price volatility of 28.63%; and expected term of 4.2 years. In general, stock options granted prior to 2023 vest after three years of continuous service, while stock options granted in 2023 are subject to graded vesting over three years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

During the three months ended March 31, 2023, the company granted 262,508 RSUs, with a weighted-average grant date fair value of $162.08 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs granted prior to 2023 vest after three years of continuous service from the grant date while RSUs granted in 2023 are subject to graded vesting over three years. The values generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

During the three months ended March 31, 2023, the company granted 99,626 PSUs with a weighted-average grant date fair value of $238.24 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies comprising the S&P 500 stock market index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&P 500 companies, which were 31.8% and 40.9%, respectively. Depending on the company’s Relative TSR performance at the end of the performance period, the recipient may earn from 0% to 200% of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

13. Stockholders' Equity

Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.

In December 2021, our Board of Directors authorized a $3.5 billion share repurchase program. As of March 31, 2023, there was $2.3 billion remaining under this authorization. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs.

Accumulated other comprehensive loss

Changes, net of tax, in accumulated other comprehensive loss, were as follows:

			Currency Translation Adjustments
					Other Currency		Benefit Plans		Accumulated Other
	Cash Flow		Net Investment		Translation		Actuarial		Comprehensive
(MILLIONS OF DOLLARS)	Hedges		Hedges		Adjustments		(Losses)/Gains		Loss
Balance, December 31, 2022	$	90	$	41	$	(944)	$	(4)	$	(817)
Other comprehensive (loss)/income, net of tax	(2)		(6)		(7)		4		(11)
Balance, March 31, 2023	$	88	$	35	$	(951)	$	—	$	(828)
Balance, December 31, 2021	$	4	$	5	$	(756)	$	(17)	$	(764)
Other comprehensive income, net of tax	26		12		21		1		60
Balance, March 31, 2022	$	30	$	17	$	(735)	$	(16)	$	(704)

16 |

14. Earnings per Share

The following table presents the calculation of basic and diluted earnings per share:

	Three Months Ended
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	March 31,
	2023		2022
Numerator
Net income before allocation to noncontrolling interests	$	551	$	594
Less: Net loss attributable to noncontrolling interests	(1)		(1)
Net income attributable to Zoetis Inc.	$	552	$	595
Denominator
Weighted-average common shares outstanding	463.5		472.2
Common stock equivalents: stock options, RSUs, PSUs and DSUs	1.1		1.9
Weighted-average common and potential dilutive shares outstanding	464.6		474.1
Earnings per share attributable to Zoetis Inc. stockholders—basic	$	1.19	$	1.26
Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	1.19	$	1.26

The number of stock options outstanding under the company's Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were not material for the three months ended March 31, 2023 and 2022.

15. Commitments and Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 8. Income Taxes.

A. Legal Proceedings

Our non-tax contingencies include, among others, the following:

•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.

•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.

•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.

•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.

The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.

Ulianopolis, Brazil

In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.

17 |

The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.

At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area.

On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. The defendants presented the technical proposal to the Prosecutor on October 21, 2019. On March 3, 2020, the Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor. On July 15, 2020, the Prosecutor recommended certain amendments to the proposal for the Phase II testing. On September 28, 2020, the parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing. Due to the ongoing issues presented by the coronavirus (COVID-19) pandemic, the parties have been unable to secure a start date for the Phase II testing and have no timeline at this point when testing will begin.

Belgium Excess Profit Tax Regime

On February 14, 2019, the General Court of the European Union (General Court) annulled the January 11, 2016 decision of the European Commission (EC) that selective tax advantages granted by Belgium under its "excess profit" tax scheme constitute illegal state aid. As a result of the 2016 decision, the company recorded a net tax charge of approximately $35 million in the first half of 2016. On May 8, 2019, the EC filed an appeal to the decision of the General Court. On September 16, 2019, the EC opened separate in-depth investigations to assess whether Belgium excess profit rulings granted to 39 multinational companies, including Zoetis, constituted state aid for those companies. On September 16, 2021, the European Court of Justice upheld the EC’s decision that the Belgium excess profit ruling system is considered an aid scheme and referred the case back to the General Court to rule on open questions. On May 24, 2022, the General Court resumed all proceedings involved with the Excess Profit Rulings cases, including Zoetis. On June 23, 2022, as requested by the General Court, the company provided observations in relations to (i) the impact of the Court of Justice’s decision that the Belgium excess profit ruling system is considered an aid scheme and (ii) the impact of recent case laws by the General Court with regards to the existence of a selective advantage. On December 16, 2022, the company submitted observations on the conclusions drawn from the November 8, 2022 Fiat Chrysler Finance Europe and Ireland v Commission judgement, as requested by the General Court. A hearing by the General Court took place on February 15, 2023 and we are now awaiting a decision on our plea. The company has not reflected any potential benefits in its condensed consolidated financial statements as of March 31, 2023 as a result of the 2019 annulment. We will continue to monitor the developments of the appeal and its ultimate resolution.

B. Guarantees and Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 31, 2023, recorded amounts for the estimated fair value of these indemnifications were not material.

16. Segment Information

Operating Segments

We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, other pharmaceutical products, dermatology, anti-infectives, medicated feed additives and animal health diagnostics, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

•    Other business activities, includes our Client Supply Services (CSS) contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.

18 |

•    Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.

•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition-related activities, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.

•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) procurement costs.

Segment Assets

We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

Selected Statement of Income Information    

	Earnings						Depreciation and Amortization(a)
	Three Months Ended						Three Months Ended
	March 31,						March 31,
(MILLIONS OF DOLLARS)	2023			2022			2023		2022
U.S.
Revenue	$	1,005		$	1,020
Cost of sales	203			185
Gross profit	802			835
Gross margin	79.8		%	81.9		%
Operating expenses	188			165
Other (income)/deductions-net	—			—
U.S. Earnings	614			670			$	19	$	13
International
Revenue(b)	978			948
Cost of sales	291			265
Gross profit	687			683
Gross margin	70.2		%	72.0		%
Operating expenses	151			145
Other (income)/deductions-net	1			—
International Earnings	535			538			21		18
Total operating segments	1,149			1,208			40		31
Other business activities	(114)			(98)			8		7
Reconciling Items:
Corporate	(208)			(259)			32		35
Purchase accounting adjustments	(42)			(40)			39		40
Acquisition-related costs	(1)			(2)			—		—
Certain significant items(c)	(22)			—			—		—
Other unallocated	(65)			(82)			1		1
Total Earnings(d)	$	697		$	727		$	120	$	114

(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

(b)    Revenue denominated in euros was $204 million and $203 million for the three months ended March 31, 2023 and 2022, respectively.

(c)    For the three months ended March 31, 2023, primarily consisted of employee termination costs related to organizational structure refinements.

For the three months ended March 31, 2022, primarily consisted of product transfer costs offset by other items.

(d)    Defined as income before provision for taxes on income.

19 |

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview of our business

Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock farmers and ranchers.

We manage our operations through two geographic operating segments: the United States (U.S.) and International. Within each of these operating segments, we offer a diversified product portfolio for both companion animal and livestock customers in order to capitalize on local and regional trends and customer needs. See Notes to Condensed Consolidated Financial Statements — Note 16. Segment Information.

We directly market our products to veterinarians and livestock producers located in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and are a market leader in nearly all of the major regions in which we operate. Through our efforts to establish an early and direct presence in many emerging markets, such as Brazil, Chile, China and Mexico, we believe we are one of the largest animal health medicines and vaccines businesses as measured by revenue across emerging markets as a whole. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.

We believe our investments in one of the industry’s largest sales organizations, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers. Our research and development (R&D) efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so that they remain relevant for our customers.

We have approximately 300 product lines that we sell in over 100 countries for the prediction, prevention, detection and treatment of diseases and conditions that affect various companion animal and livestock species. The diversity of our product portfolio and our global operations provides stability to our overall business. For instance, in livestock, impacts on our revenue that may result from disease outbreaks or weather conditions in a particular market or region are often offset by increased sales in other regions from exports and other species as consumers shift to other animal proteins.

A summary of our 2023 performance compared with the comparable 2022 period follows:

					% Change
	Three Months Ended					Related to
	March 31,					Foreign
(MILLIONS OF DOLLARS)	2023		2022		Total	Exchange	Operational(a)
Revenue	$	2,000	$	1,986	1	(3)	4
Net income attributable to Zoetis	552		595		(7)	—	(7)
Adjusted net income(a)	607		625		(3)	—	(3)

(a)    Operational growth and adjusted net income are non-GAAP financial measures. See the Non-GAAP financial measures section of this Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) for more information.

Our operating environment

For a description of our operating environment, including factors which could materially affect our business, financial condition, or future results, see "Our Operating Environment" in the MD&A of our 2022 Annual Report on Form 10-K. Set forth below are updates to certain of the factors disclosed in our 2022 Annual Report on Form 10-K.

Quarterly Variability of Financial Results

Our quarterly financial results are subject to variability related to a number of factors including, but not limited to: the continuing decline in global macroeconomic conditions, global supply chain disruption, Russia’s invasion of Ukraine, variability in distributor inventory stocking levels as a result of expected demand and promotional activities, weather patterns, herd management decisions, regulatory actions, inflation, competitive dynamics, disease outbreaks, the impact of the COVID-19 pandemic, product and geographic mix, timing of price increases and timing of investment decisions.

Global Supply Chain Disruption

We are seeing improvements and recovery in supply for certain products as compared to the prior year. However, we continue to have supply chain challenges for other products and component parts, as well as competition for manufacturing inputs. Our global manufacturing team remains committed to addressing specific issues with ongoing supply chain optimizations, controlled launches for new products in additional markets and customer coordination.

Disease Outbreaks

Sales of our livestock products have in the past, and may in the future be, adversely affected by the outbreak of disease carried by animals. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Alternatively, sales of products that treat specific disease outbreaks may increase.

20 |

Foreign Exchange Rates

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 100 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. For the three months ended March 31, 2023, approximately 45% of our revenue was denominated in foreign currencies. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. As we operate in multiple foreign currencies, including the Australian dollar, Brazilian real, British pound, Canadian dollar, Chinese yuan, euro and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue, cost of goods and expenses, and consequently, net income. Exchange rate fluctuations may also have an impact beyond our reported financial results and directly impact operations. These fluctuations may affect the ability to buy and sell our goods and services between markets impacted by significant exchange rate variances. For the three months ended March 31, 2023, approximately 55% of our total revenue was in U.S. dollars. Our year-over-year total revenue growth was unfavorably impacted by approximately 3% from changes in foreign currency values relative to the U.S. dollar. For operations in highly inflationary economies, we translate monetary items at rates in effect at the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.

Non-GAAP financial measures

We report information in accordance with U.S. generally accepted accounting principles (GAAP). Management also measures performance using non-GAAP financial measures that may exclude certain amounts from the most directly comparable GAAP measure. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP financial measures have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors and may not be comparable to the calculation of similar measures of other companies. We present certain identified non-GAAP measures solely to provide investors with useful information to more fully understand how management assesses performance.

Operational Growth

We believe that it is important to not only understand overall revenue and earnings growth, but also “operational growth.” Operational growth is a non-GAAP financial measure defined as revenue or earnings growth excluding the impact of foreign exchange. This measure provides information on the change in revenue and earnings as if foreign currency exchange rates had not changed between the current and prior periods to facilitate a period-to-period comparison. We believe this non-GAAP measure provides a useful comparison to previous periods for the company and investors, but should not be viewed as a substitute for U.S. GAAP reported growth.

Adjusted Net Income and Adjusted Earnings Per Share

Adjusted net income and the corresponding adjusted earnings per share (EPS) are non-GAAP financial measures of performance used by management. We believe these financial measures are useful supplemental information to investors when considered together with our U.S. GAAP financial measures. We report adjusted net income to portray the results of our major operations, and the discovery, development, manufacture and commercialization of our products, prior to considering certain income statement elements. We define adjusted net income and adjusted EPS as net income attributable to Zoetis and EPS before the impact of purchase accounting adjustments, acquisition-related costs and certain significant items.

We recognize that, as an internal measure of performance, the adjusted net income and adjusted EPS measures have limitations, and we do not restrict our performance management process solely to these metrics. A limitation of the adjusted net income and adjusted EPS measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies. The adjusted net income and adjusted EPS measures are not, and should not be viewed as, a substitute for U.S. GAAP reported net income attributable to Zoetis and reported EPS. See the Adjusted Net Income section below for more information.

21 |

Analysis of the condensed consolidated statements of income

The following discussion and analysis of our statements of income should be read along with our condensed consolidated financial statements and the notes thereto included elsewhere in Part I— Item 1 of this Quarterly Report on Form 10-Q.

	Three Months Ended
	March 31,						%
(MILLIONS OF DOLLARS)	2023			2022			Change
Revenue	$	2,000		$	1,986		1
Costs and expenses:
Cost of sales	588			569			3
% of revenue	29.4		%	28.7		%
Selling, general and administrative expenses	505			465			9
% of revenue	25		%	23		%
Research and development expenses	142			122			16
% of revenue	7		%	6		%
Amortization of intangible assets	37			41			(10)
Restructuring charges and certain acquisition-related costs	21			2			*
Interest expense, net of capitalized interest	63			53			19
Other (income)/deductions—net	(53)			7			*
Income before provision for taxes on income	697			727			(4)
% of revenue	35		%	37		%
Provision for taxes on income	146			133			10
Effective tax rate	20.9		%	18.3		%
Net income before allocation to noncontrolling interests	551			594			(7)
Less: Net loss attributable to noncontrolling interests	(1)			(1)			—
Net income attributable to Zoetis Inc.	$	552		$	595		(7)
% of revenue	28		%	30		%

*Calculation not meaningful

Revenue

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Total revenue increased by $14 million, or 1%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, an increase of $79 million, or 4%, on an operational basis. Operational revenue growth was comprised primarily of the following:

•price growth of approximately 5%;

•volume growth from new products of approximately 1%,

partially offset by:

•volume decrease from key dermatology products of approximately 1%; and

•volume decrease from other in-line products of approximately 1%.

Foreign exchange decreased reported revenue growth by approximately 3%.

Costs and Expenses

Cost of sales
	Three Months Ended
	March 31,						%
(MILLIONS OF DOLLARS)	2023			2022			Change
Cost of sales	$	588		$	569		3
% of revenue	29.4		%	28.7		%

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Cost of sales as a percentage of revenue was 29.4% in the three months ended March 31, 2023, compared with 28.7% in the three months ended March 31, 2022. The increase was primarily as a result of:

•unfavorable manufacturing and other costs;

•unfavorable product mix; and

•inventory obsolescence, scrap and other charges,

partially offset by:

•favorable foreign exchange; and

22 |

•price increases.

Selling, general and administrative expenses
	Three Months Ended
	March 31,						%
(MILLIONS OF DOLLARS)	2023			2022			Change
Selling, general and administrative expenses	$	505		$	465		9
% of revenue	25		%	23		%

Three months ended March 31, 2023 vs. three months ended March 31, 2022

SG&A expenses increased by $40 million, or 9%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, primarily as a result of:

•certain compensation-related costs primarily due to timing of new hires in 2022;

•higher travel and entertainment expenses; and

•higher freight and logistics costs;

partially offset by:

•favorable foreign exchange; and

•lower bad debt reserves for accounts receivable.

Research and development expenses
	Three Months Ended
	March 31,						%
(MILLIONS OF DOLLARS)	2023			2022			Change
Research and development expenses	$	142		$	122		16
% of revenue	7		%	6		%

Three months ended March 31, 2023 vs. three months ended March 31, 2022

R&D expenses increased by $20 million, or 16%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, primarily as a result of:

•an increase in certain compensation-related costs to support innovation;

•higher other operating costs; and

•increased spending driven by project investments,

partially offset by:

•favorable foreign exchange.

Amortization of intangible assets
	Three Months Ended
	March 31,				%
(MILLIONS OF DOLLARS)	2023		2022		Change
Amortization of intangible assets	$	37	$	41	(10)

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Amortization of intangible assets decreased in the three months ended March 31, 2023 versus the comparable prior year period primarily due to asset impairments taken in 2022 and assets that became fully amortized during 2022, partially offset by intangible assets acquired during 2022.

Restructuring charges and certain acquisition-related costs
	Three Months Ended
	March 31,				%
(MILLIONS OF DOLLARS)	2023		2022		Change
Restructuring charges and certain acquisition-related costs	$	21	$	2	*

* Calculation not meaningful

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Restructuring charges and certain acquisition-related costs were $21 million and $2 million in the three months ended March 31, 2023 and 2022, respectively. Restructuring charges and certain acquisition-related costs in the three months ended March 31, 2023 primarily consisted of employee termination costs related to organizational structure refinements. Restructuring charges and certain acquisition-related costs in the three months ended March 31, 2022 primarily consisted of integration costs related to recent acquisitions.

23 |

Interest expense, net of capitalized interest
	Three Months Ended
	March 31,				%
(MILLIONS OF DOLLARS)	2023		2022		Change
Interest expense, net of capitalized interest	$	63	$	53	19

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Interest expense, net of capitalized interest, increased by $10 million, or 19%, in the three months ended March 31, 2023 versus the comparable prior year period. The increase was primarily as a result of higher interest rates on the $1.35 billion aggregate principal amount of our 2022 senior notes issued in November 2022 as compared to the 2013 senior notes redeemed in February 2023, upon maturity, as well as a higher debt balance during a portion of the current period. This increase was partially offset by higher gains on foreign exchange derivative instruments as compared to the prior year period.

Other (income)/deductions—net
	Three Months Ended
	March 31,				%
(MILLIONS OF DOLLARS)	2023		2022		Change
Other (income)/deductions—net	$	(53)	$	7	*

*Calculation not meaningful

Three months ended March 31, 2023 vs. three months ended March 31, 2022

The change in Other (income)/deductions—net in the three months ended March 31, 2023 versus the comparable prior year period was primarily as a result of royalty-related income that was predominantly associated with a settlement for underpayment of royalties in prior periods and higher interest income in the current period due to higher interest rates on cash balances denominated in the U.S. dollar.

Provision for taxes on income
	Three Months Ended
	March 31,						%
(MILLIONS OF DOLLARS)	2023			2022			Change
Provision for taxes on income	$	146		$	133		10
Effective tax rate	20.9		%	18.3		%

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Our effective tax rate was 20.9% for the three months ended March 31, 2023, compared with 18.3% for the three months ended March 31, 2022. The higher effective tax rate for the three months ended March 31, 2023 was attributable to lower net discrete tax benefits for the three months ended March 31, 2023 and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income for the three months ended March 31, 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.

24 |

Operating Segment Results

On a global basis, the mix of revenue between companion animal and livestock products was as follows:

					% Change
	Three Months Ended					Related to
	March 31,					Foreign
(MILLIONS OF DOLLARS)	2023		2022		Total	Exchange	Operational
U.S.
Companion animal	$	721	$	774	(7)	—	(7)
Livestock	284		246		15	—	15
	1,005		1,020		(1)	—	(1)
International
Companion animal	504		489		3	(7)	10
Livestock	474		459		3	(7)	10
	978		948		3	(7)	10
Total
Companion animal	1,225		1,263		(3)	(3)	—
Livestock	758		705		8	(4)	12
Contract manufacturing & human health	17		18		(6)	(2)	(4)
	$	2,000	$	1,986	1	(3)	4

Earnings by segment and the operational and foreign exchange changes versus the comparable prior year period were as follows:

							% Change
	Three Months Ended							Related to
	March 31,							Foreign
(MILLIONS OF DOLLARS)	2023			2022			Total	Exchange	Operational
U.S.
Revenue	$	1,005		$	1,020		(1)	—	(1)
Cost of Sales	203			185			10	—	10
Gross Profit	802			835			(4)	—	(4)
Gross Margin	79.8		%	81.9		%
Operating Expenses	188			165			14	—	14
Other (income)/deductions-net	—			—			*	*	*
U.S. Earnings	614			670			(8)	—	(8)
International
Revenue	978			948			3	(7)	10
Cost of Sales	291			265			10	(10)	20
Gross Profit	687			683			1	(5)	6
Gross Margin	70.2		%	72.0		%
Operating Expenses	151			145			4	(7)	11
Other (income)/deductions-net	1			—			*	*	*
International Earnings	535			538			(1)	(5)	4
Total operating segments	1,149			1,208			(5)	(2)	(3)
Other business activities	(114)			(98)			16
Reconciling Items:
Corporate	(208)			(259)			(20)
Purchase accounting adjustments	(42)			(40)			5
Acquisition-related costs	(1)			(2)			(50)
Certain significant items	(22)			—			*
Other unallocated	(65)			(82)			(21)
Total Earnings	$	697		$	727		(4)

* Calculation not meaningful

25 |

Three months ended March 31, 2023 vs. three months ended March 31, 2022

U.S. operating segment

U.S. segment revenue decreased by $15 million, or 1%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, reflecting a decrease of $53 million in companion animal products, partially offset by an increase of $38 million in livestock products.

•Companion animal revenue in the quarter was impacted by distributor de-stocking across the portfolio, as well as purchases in the fourth quarter of 2022 ahead of expected price increases and based on promotional activities. Revenue declined due to small animal parasiticides, anti-infectives and key dermatology, partially offset by our mAb product, Solensia.

•Livestock revenue grew due to cattle and poultry, partially offset by a decline in swine. Sales of cattle products grew due to improved supply of key products and higher distributor inventory levels. Sales of products in our poultry portfolio grew due to increases in vaccines and biodevices. Sales of swine products declined due to decreased disease prevalence.

U.S. segment earnings decreased by $56 million, or 8%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, primarily due to higher operating expenses and cost of sales, as well as lower revenue.

International operating segment

International segment revenue increased by $30 million, or 3%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022. Operational revenue increased by $95 million, or 10%, driven by growth of $49 million in companion animal products and growth of $46 million in livestock products.

•Companion animal operational revenue growth was driven primarily by the recent launches of our mAb products, Librela and Solensia, as well as growth in the Simparica franchise.

•Livestock operational revenue growth was due to increased sales of cattle, sheep, poultry and fish products. Sales of cattle products grew due to price and favorable market conditions in key and emerging markets. Sales of sheep products grew as a result of favorable market conditions in Australia and the acquisition of Jurox. Sales of poultry products grew due to market growth, demand generation efforts and price in key poultry markets. Growth in our fish portfolio was primarily the result of increased sales of vaccines across key salmon markets, primarily Norway.

•Additionally, International segment revenue was unfavorably impacted by foreign exchange which decreased revenue by $65 million, or 7%, primarily driven by the euro, Argentinian peso, Chinese renminbi, British pound and Japanese yen.

International segment earnings decreased by $3 million, or 1%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022. Operational earnings growth was $24 million, or 4%, primarily due to revenue, partially offset by higher cost of sales and operating expenses.

Other business activities

Other business activities includes our Client Supply Services contract manufacturing results, our human health business and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the International segment.

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Other business activities net loss increased by $16 million in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, reflecting an increase in R&D costs due to an increase in certain compensation-related costs to support innovation, an increase in operating costs and an increase in project investments, as well as lower earnings in our human health business, partially offset by favorable foreign exchange.

Reconciling items

Reconciling items include certain costs that are not allocated to our operating segments results, such as costs associated with the following:

•Corporate, which includes certain costs associated with information technology, facilities, legal, finance, human resources, business development and communications, among others. These costs also include certain compensation costs, certain procurement costs, and other miscellaneous operating expenses that are not charged to our operating segments, as well as interest income and expense;

•Certain transactions and events such as (i) Purchase accounting adjustments, which includes expenses associated with the amortization of fair value adjustments to inventory, intangible assets, and property, plant and equipment; (ii) Acquisition-related activities, which includes costs for acquisitions and integration; and (iii) Certain significant items, which includes non-acquisition-related restructuring charges, certain asset impairment charges, certain legal and commercial settlements, and costs associated with cost reduction/productivity initiatives; and

•Other unallocated, which includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Corporate expenses decreased by $51 million, or 20%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, primarily associated with a settlement for underpayment of royalties in prior periods, favorable interest income and favorable foreign exchange, partially offset by higher interest expense, increases in professional services and investments in information technology.

Other unallocated expenses decreased by $17 million, or 21%, in the three months ended March 31, 2023, compared with the three months ended March 31, 2022, primarily due to favorable foreign exchange and lower freight charges, partially offset by inventory obsolescence and scrap.

See Notes to Condensed Consolidated Financial Statements—Note 16. Segment Information for further information.

26 |

Adjusted net income

General description of adjusted net income (a non-GAAP financial measure)

Adjusted net income is an alternative view of performance used by management, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. The adjusted net income measure is an important internal measurement for us. Additionally, we measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how the adjusted net income measure is utilized:

•senior management receives a monthly analysis of our operating results that is prepared on an adjusted net income basis;

•our annual budgets are prepared on an adjusted net income basis; and

•other goal setting and performance measurements.

Purchase accounting adjustments

Adjusted net income is calculated prior to considering certain significant purchase accounting impacts that result from business combinations and net asset acquisitions. These impacts, primarily associated with certain acquisitions, include amortization related to the increase in fair value of the acquired finite-lived intangible assets and depreciation related to the increase/decrease to fair value of the acquired fixed assets. Therefore, the adjusted net income measure includes the revenue earned upon the sale of the acquired products without considering the aforementioned significant charges.

While certain purchase accounting adjustments can occur through 20 or more years, this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by providing a degree of parity to internally developed intangible assets for which R&D costs previously have been expensed.

A completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through adjusted net income. These components of adjusted net income are derived solely from the impact of the items listed above. We have not factored in the impact of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting revenue, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our adjusted net income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.

Acquisition-related costs

Adjusted net income is calculated prior to considering transaction and integration costs associated with significant business combinations or net asset acquisitions because these costs are unique to each transaction and represent costs that were incurred to acquire and integrate certain businesses as a result of the acquisition decision. We have made no adjustments for the resulting synergies.

We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in the ordinary course of business.

The integration costs associated with a business combination may occur over several years, with the more significant impacts generally ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the regulated nature of the animal health medicines, vaccines and diagnostic business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the U.S. Food and Drug Administration and/or other regulatory authorities.

Certain significant items

Adjusted net income is calculated excluding certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be nonrecurring; or items that relate to products that we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be costs related to a major non-acquisition-related restructuring charge and associated implementation costs for a program that is specific in nature with a defined term, such as those related to our non-acquisition-related cost-reduction and productivity initiatives; amounts related to disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; certain asset impairments; adjustments related to the resolution of certain tax positions; significant currency devaluation; the impact of adopting certain significant, event-driven tax legislation; or charges related to legal matters. See Notes to Condensed Consolidated Financial Statements—Note 15. Commitments and Contingencies. Our normal, ongoing defense costs or settlements of and accruals on legal matters made in the normal course of our business would not be considered certain significant items.

27 |

Reconciliation

A reconciliation of net income attributable to Zoetis, as reported under U.S. GAAP, to adjusted net income follows:

	Three Months Ended
	March 31,				%
(MILLIONS OF DOLLARS)	2023		2022		Change
GAAP reported net income attributable to Zoetis	$	552	$	595	(7)
Purchase accounting adjustments—net of tax	34		30		13
Acquisition-related costs—net of tax	1		1		—
Certain significant items—net of tax	20		(1)		*
Non-GAAP adjusted net income(a)	$	607	$	625	(3)

*Calculation not meaningful

(a)    The effective tax rate on adjusted pretax income was 20.5% and 18.9% for the three months ended March 31, 2023 and 2022, respectively.

The higher effective tax rate for the three months ended March 31, 2023, compared with the three months ended March 31, 2022, was attributable to lower net discrete tax benefits for the three months ended March 31, 2023 and less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income for the three months ended March 31, 2023. Jurisdictional mix of earning can vary depending on repatriation decision, operating fluctuations in the normal course of business and the impact of non-deductible and non-taxable items.

A reconciliation of reported diluted earnings per share (EPS), as reported under U.S. GAAP, to non-GAAP adjusted diluted EPS follows:

	Three Months Ended
	March 31,				%
	2023		2022		Change
Earnings per share—diluted(a):
GAAP reported EPS attributable to Zoetis —diluted	$	1.19	$	1.26	(6)
Purchase accounting adjustments—net of tax	0.07		0.06		17
Acquisition-related costs—net of tax	—		—		*
Certain significant items—net of tax	0.05		—		*
Non-GAAP adjusted EPS—diluted	$	1.31	$	1.32	(1)

* Calculation not meaningful

(a)    Diluted earnings per share was computed using the weighted-average common shares outstanding during the period plus the common stock equivalents related to stock options, restricted stock units, performance-vesting restricted stock units and deferred stock units.

Adjusted net income includes the following charges for each of the periods presented:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Interest expense, net of capitalized interest	$	63	$	53
Interest income	33		2
Income taxes	156		145
Depreciation	72		61
Amortization	9		13

28 |

Adjusted net income, as shown above, excludes the following items:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Purchase accounting adjustments:
Amortization and depreciation	$	39	$	40
Cost of sales	3		—
Total purchase accounting adjustments—pre-tax	42		40
Income taxes(a)	8		10
Total purchase accounting adjustments—net of tax	34		30
Acquisition-related costs:
Integration costs	1		2
Total acquisition-related costs—pre-tax	1		2
Income taxes(a)	—		1
Total acquisition-related costs—net of tax	1		1
Certain significant items:
Other restructuring charges and cost-reduction/productivity initiatives(b)	20		2
Other	2		(2)
Total certain significant items—pre-tax	22		—
Income taxes(a)	2		1
Total certain significant items—net of tax	20		(1)
Total purchase accounting adjustments, acquisition-related costs, and certain significant items—net of tax	$	55	$	30

(a)    Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

    Income taxes in Purchase accounting adjustments also includes tax benefits related to a deferred adjustment as a result of a change in tax basis for the three months ended March 31, 2022.

(b)    For the three months ended March 31, 2023, primarily consisted of employee termination costs related to organizational structure refinements.

For the three months ended March 31, 2022, primarily consisted of product transfer costs.

29 |

The classification of the above items excluded from adjusted net income are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Cost of sales:
Purchase accounting adjustments	$	4	$	1
Other	—		3
Total Cost of sales	4		4
Selling, general & administrative expenses:
Purchase accounting adjustments	7		7
Total Selling, general & administrative expenses	7		7
Amortization of intangible assets:
Purchase accounting adjustments	31		32
Total Amortization of intangible assets	31		32
Restructuring charges and certain acquisition-related costs:
Integration costs	1		2
Employee termination costs	20		—
Total Restructuring charges and certain acquisition-related costs	21		2
Other (income)/deductions—net:
Other	2		(3)
Total Other (income)/deductions—net	2		(3)
Provision for taxes on income	10		12
Total purchase accounting adjustments, acquisition-related costs, and certain significant items—net of tax	$	55	$	30

Analysis of the condensed consolidated statements of comprehensive income

Changes in other comprehensive income for the periods presented are primarily related to foreign currency translation adjustments and unrealized gains/(losses) on derivative instruments. The foreign currency translation adjustment changes result from the strengthening or weakening of the U.S. dollar as compared to the currencies in the countries in which we do business. Unrealized gains/(losses) on the changes in the fair value of derivative instruments are recorded within Accumulated other comprehensive income/(loss) and reclassified into earnings depending on the nature and purpose of the financial instrument, as described in Note 9. Financial Instruments of the Notes to Condensed Consolidated Financial Statements.

Analysis of the condensed consolidated balance sheets

March 31, 2023 vs. December 31, 2022

For a discussion about the changes in Cash and cash equivalents, Short-term borrowings, Current portion of long-term debt and Long-term debt, net of discount and issuance costs, see “Analysis of financial condition, liquidity and capital resources” below.

Inventories increased primarily as a result of the increase in demand and build-up of certain products, as well as lower sales than anticipated for certain products.

Other current assets increased primarily due to the reclassification of certain assets from long-term to short-term, as well as the timing of tax benefits recognized, partially offset by the mark-to-market adjustment of derivative instruments.

Property, plant and equipment increased primarily as a result of capital spending, partially offset by depreciation expense .

Accrued compensation and related items decreased due to the payments of 2022 annual incentive bonuses, savings plan contributions to eligible employees and payments for sales incentive bonuses, as well as the timing of the bi-weekly payroll, partially offset by the accrual of 2023 annual incentive bonuses, sales incentive bonuses and savings plan contributions to eligible employees.

The net changes in Noncurrent deferred tax assets, Noncurrent deferred tax liabilities, Income taxes payable and Other taxes payable primarily reflect adjustments to the accrual for the income tax provision, the timing of income tax payments, the tax impact of various acquisitions and the impact of the remeasurement of deferred taxes as a result of changes in tax rates.

For an analysis of the changes in Total Equity, see the Condensed Consolidated Statements of Equity and Notes to Condensed Consolidated Financial Statements— Note 13. Stockholders' Equity.

30 |

Analysis of the condensed consolidated statements of cash flows

	Three Months Ended
	March 31,				$
(MILLIONS OF DOLLARS)	2023		2022		Change
Net cash provided by (used in):
Operating activities	$	549	$	309	$	240
Investing activities	(216)		(118)		(98)
Financing activities	(1,802)		(545)		(1,257)
Effect of exchange-rate changes on cash and cash equivalents	(3)		4		(7)
Net decrease in cash and cash equivalents	$	(1,472)	$	(350)	$	(1,122)

Operating activities

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Net cash provided by operating activities was $549 million for the three months ended March 31, 2023, and $309 million for the three months ended March 31, 2022. The increase in operating cash flows was primarily attributable to the timing of receipts and payments in the ordinary course of business and higher net income as adjusted by non-cash items, partially offset by the inventory build-up of certain products for increased demand and to mitigate potential supply constraints.

Investing activities

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Our net cash used in investing activities was $216 million for the three months ended March 31, 2023, compared with net cash used in investing activities of $118 million for the three months ended March 31, 2022. The net cash used in investing activities for the three months ended March 31, 2023 and 2022 was primarily due to capital expenditures.

Financing activities

Three months ended March 31, 2023 vs. three months ended March 31, 2022

Our net cash used in financing activities was $1,802 million for the three months ended March 31, 2023, compared with net cash used in financing activities of $545 million for the three months ended March 31, 2022. The net cash used in financing activities for the three months ended March 31, 2023 was primarily attributable to the repayment of the $1.35 billion aggregate principal amount of our 2013 senior notes due 2023 in February 2023, the purchase of treasury shares, the payment of dividends and taxes paid on withholding shares, partially offset by proceeds in connection with the issuance of common stock under our equity incentive plan. The net cash used in financing activities for the three months ended March 31, 2022 was primarily attributable to the purchase of treasury shares, the payment of dividends and taxes paid on withholding shares, partially offset by proceeds in connection with the issuance of common stock under our equity incentive plan.

Analysis of financial condition, liquidity and capital resources

While we believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our cash needs for the next twelve months and beyond, this may be subject to the environment in which we operate. Risks to our meeting future funding requirements include global economic conditions described in the following paragraph.

Global financial markets may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position. While we do not anticipate it, there can be no assurance that a challenging economic environment or an economic downturn will not impact our liquidity or our ability to obtain future financing.

Selected measures of liquidity and capital resources

Certain relevant measures of our liquidity and capital resources follow:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
Cash and cash equivalents	$	2,109	$	3,581
Accounts receivable, net(a)	1,186		1,215
Short-term borrowings	3		2
Current portion of long-term debt	—		1,350
Long-term debt	6,559		6,552
Working capital	4,354		4,339
Ratio of current assets to current liabilities	3.27:1		2.37:1

(a)    Accounts receivable are usually collected over a period of 45 to 75 days. For the three months ended March 31, 2023 compared with December 31, 2022, the number of days that accounts receivables were outstanding remained within this range. We regularly monitor our accounts receivable for collectability, particularly in markets where economic conditions remain uncertain. We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on such factors as past due aging, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment.

For additional information about the sources and uses of our funds, see the Analysis of the condensed consolidated balance sheets and Analysis of the condensed consolidated statements of cash flows sections of this MD&A.

31 |

Credit facility and other lines of credit

In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. The credit facility replaced the company's existing revolving credit facility dated as of December 2016. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.

We were in compliance with all financial covenants as of March 31, 2023 and December 31, 2022. There were no amounts drawn under the credit facility as of March 31, 2023 or December 31, 2022.

We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of March 31, 2023, we had access to $51 million of lines of credit which expire at various times and are generally renewed annually. There were $3 million of borrowings outstanding related to these facilities as of March 31, 2023 and $2 million of borrowings outstanding related to these facilities as of December 31, 2022.

Domestic and international short-term funds

Many of our operations are conducted outside the U.S. The amount of funds held in the U.S. will fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of U.S. and international cash flows (both inflows and outflows). Actual repatriation of overseas funds can result in additional U.S. and local income taxes, such as U.S. state income taxes, local withholding taxes, and taxes on currency gains and losses.

Global economic conditions

Challenging economic conditions in recent years have not had, nor do we anticipate that it will have, a significant impact on our liquidity. Due to our operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have the ability to meet our liquidity needs for the foreseeable future. As markets change, we continue to monitor our liquidity position. There can be no assurance that a challenging economic environment or an economic downturn would not impact our ability to obtain financing in the future.

Debt securities

On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.

Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale lease-back transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which, the senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

32 |

Our outstanding debt securities are as follows:

Description	Principal Amount	Interest Rate	Terms
2015 Senior Notes due 2025	$750 million	4.500%	Interest due semi annually, not subject to amortization, aggregate principal due on November 13, 2025
2022 Senior Notes due 2025	$600 million	5.400%	Interest due semi annually, not subject to amortization, aggregate principal due on November 14, 2025
2017 Senior Notes due 2027	$750 million	3.000%	Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2027
2018 Senior Notes due 2028	$500 million	3.900%	Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2028
2020 Senior Notes due 2030	$750 million	2.000%	Interest due semi annually, not subject to amortization, aggregate principal due on May 15, 2030
2022 Senior Notes due 2032	$750 million	5.600%	Interest due semi annually, not subject to amortization, aggregate principal due on November 16, 2032
2013 Senior Notes due 2043	$1,150 million	4.700%	Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2043
2017 Senior Notes due 2047	$500 million	3.950%	Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2047
2018 Senior Notes due 2048	$400 million	4.450%	Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2048
2020 Senior Notes due 2050	$500 million	3.000%	Interest due semi annually, not subject to amortization, aggregate principal due on May 15, 2050

Credit ratings

Two major corporate debt-rating organizations, Moody's and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:

	Commercial Paper	Long-term Debt		Date of Last Action
Name of Rating Agency	Rating	Rating	Outlook
Moody’s	P-2	Baa1	Stable	August 2017
S&P	A-2	BBB	Stable	December 2016

Share repurchase program

In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of March 31, 2023, there was $2.3 billion remaining under this authorization. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs. Share repurchases may be executed through various means, including open market or privately negotiated transactions. During the first three months of 2023, 1.7 million shares were repurchased for $283 million, which excludes a $2 million accrual for excise tax on net share repurchases.

Off-balance sheet arrangements

In the ordinary course of business and in connection with the sale of assets and businesses, we may indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 31, 2023 and December 31, 2022, recorded amounts for the estimated fair value of these indemnifications are not material.

New accounting standards

There were no accounting standards that were recently issued but not adopted as of March 31, 2023 that the Company expects to have a material impact on its condensed consolidated financial statements.

Forward-looking statements and factors that may affect future results

This report contains “forward-looking” statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally identify forward-looking statements by using words such as “anticipate,” “estimate,” “could,” “expect,” “intend,” “project,” “plan,” “predict,” “believe,” “seek,” “continue,” “outlook,” “objective,” “target,” “may,” “might,” “will,” “should,” “can have,” “likely” or the negative version of these words or comparable words or by using future dates in connection with any discussion of future performance, actions or events.

In particular, forward-looking statements include statements relating to our future actions, business plans or prospects, prospective products, product approvals or products under development, product and supply chain disruptions, R&D costs, timing and likelihood of success, future operating or financial performance, future results of current and anticipated products and services, the impact of the COVID-19 pandemic, strategies, sales efforts, expenses, production efficiencies, production margins, anticipated timing of generic market entries, integration of acquired businesses, interest rates, tax rates, changes in tax regimes and laws, foreign exchange rates, growth in emerging markets, the outcome of contingencies, such as legal proceedings, plans related to share repurchases and dividends, government regulation and financial results. These statements are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties, many of which are beyond our control, and are based on assumptions that could prove to be inaccurate. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

33 |

•unanticipated safety, quality or efficacy concerns or issues about our products,

•the possible impact and timing of competing products, including generic alternatives, on our products and our ability to compete against such products;

•the continuing decline in global economic conditions, including the current crisis in Ukraine, and inflation;

•the economic, political, legal and business environment of the foreign jurisdictions in which we do business;

•the impact of the COVID-19 global pandemic on our business, global supply chain, customers and workforce;

•disruptive innovations and advances in medical practices and technologies;

•consolidation of our customers and distributors;

•changes in the distribution channel for companion animal products;

•an outbreak of infectious disease carried by animals;

•restrictions and bans on the use of and consumer preferences regarding antibacterials in food-producing animals;

•perceived adverse effects linked to the consumption of food derived from animals that utilize our products or animals generally;

•increased regulation or decreased governmental support relating to the raising, processing or consumption of food-producing animals;

•failure to successfully acquire businesses, license rights or products, integrate businesses, form and manage alliances or divest businesses;

•adverse weather conditions and the availability of natural resources;

•the impact of climate change on our activities and the activities of our customers and suppliers, including, for example, altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and other natural disasters, rising sea levels, and rising heat index;

•failure of our R&D, acquisition and licensing efforts to generate new products and product lifecycle innovations;

•difficulties or delays in the development or commercialization of new products;

•product launch delays, inventory shortages, recalls or unanticipated costs caused by manufacturing problems and capacity imbalances;

•fluctuations in foreign exchange rates and potential currency controls;

•legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns, commercial disputes and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;

•failure to protect our intellectual property rights or to operate our business without infringing the intellectual property rights of others;

•a cyber-attack, information security breach or other misappropriation of our data;

•quarterly fluctuations in demand and costs;

•governmental laws and regulations affecting domestic and foreign operations, including without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending or possible future proposals;

•governmental laws and regulations affecting our interactions with veterinary healthcare providers; and

•the other factors set forth under "Risk Factors" in Item 1A. of Part I of our 2022 Annual Report on Form 10-K.

However, there may also be other risks that we are unable to predict at this time. These risks or uncertainties may cause actual results to differ materially from those contemplated by a forward-looking statement. You should not put undue reliance on forward-looking statements. Forward-looking statements speak only as of the date on which they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q and 8-K reports and our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the above to be a complete discussion of all potential risks or uncertainties.

34 |

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

A significant portion of our revenue and costs are exposed to changes in foreign exchange rates. In addition, our outstanding borrowings may be subject to risk from changes in interest rates and foreign exchange rates. The overall objective of our financial risk management program is to seek to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and by using certain financial instruments. These practices may change as economic conditions change.

For a complete discussion of our exposure to interest rate and foreign exchange risk, refer to Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes from the information discussed therein.

Item 4.    Controls and Procedures

Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the company's management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation as of March 31, 2023, the company's Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures are effective at a reasonable level of assurance in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.

Changes in Internal Control over Financial Reporting

During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

35 |

PART II — OTHER INFORMATION

Item 1.    Legal Proceedings

The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements—Note 15. Commitments and Contingencies in Part I— Item 1, of this Quarterly Report on Form 10-Q.

Item 1A.     Risk Factors

In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in the "Our Operating Environment" and "Forward-Looking Statements and Factors That May Affect Future Results" sections of the MD&A and in Part I, Item 1A. "Risk Factors," of our 2022 Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results and which are incorporated by reference herein. There have been no material changes from the risk factors disclosed in our 2022 Annual Report on Form 10-K.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of March 31, 2023 there was $2.3 billion remaining under this program.

The following table provides information with respect to the shares of the company’s common stock repurchased during the three months ended

March 31, 2023:

	Issuer Purchases of Equity Securities(b)
	Total Number of Shares Purchased(a)	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
January 1 - January 31, 2023	358,928	$160.29	358,212	$2,529,622,653
February 1 - February 28, 2023	653,804	$164.83	575,956	$2,434,189,959
March 1 - March 31, 2023	795,412	$165.08	787,494	$2,303,728,782
	1,808,144	$164.04	1,721,662	$2,303,728,782

(a)     The company repurchased 86,482 shares during the three-month period ended March 31, 2023 that were not part of the publicly announced share repurchase authorization. These shares were reacquired from employees to satisfy tax withholding requirements on the vesting of restricted shares from equity-based awards.

(b)    Amounts exclude the impact of excise tax on net share repurchases.

Item 3.    Defaults Upon Senior Securities

None

Item 4.    Mine Safety Disclosures

None

Item 5.    Other Information

None

Item 6.    Exhibits

Exhibit 10.1	Form of Non-Employee Director Restricted Stock Unit Award Agreement, effective as of February 8, 2023*
Exhibit 10.2	Form of Cash Restricted Stock Unit Award Agreement, effective as of February 8, 2023*
Exhibit 31.1	Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Exhibit 31.2	Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Exhibit 32.1	Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
Exhibit 32.2	Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
EX-101.INS	Inline XBRL INSTANCE DOCUMENT
EX-101.SCH	Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
EX-101.CAL	Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.LAB	Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE	Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
EX-101.DEF	Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Management contracts or compensatory plans or arrangements

36 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Zoetis Inc.
May 4, 2023	By:	/S/ KRISTIN C. PECK
		Kristin C. Peck
		Chief Executive Officer and Director
May 4, 2023	By:	/S/ WETTENY JOSEPH
		Wetteny Joseph
		Executive Vice President and Chief Financial Officer

37 |

EX-10.1

Exhibit 10.1

ZOETIS INC.

2013 EQUITY AND INCENTIVE PLAN

DIRECTOR RESTRICTED STOCK UNIT AWARD

Zoetis Inc. (the “Company”) has granted to the person named below (the “Participant”), an Award of Restricted Stock Units under Section 8.1 of the Zoetis Inc. 2013 Equity and Incentive Plan, as amended and restated (the “Plan”). This Award is subject to all of the terms, definitions and provisions of this Restricted Stock Unit Award (this “RSU Award”) and the Plan, which is incorporated herein by reference, as follows:

Participant Name:            _______________

Date of Grant:    _______________

Number of Restricted Stock Units:     _______________

Unless otherwise defined in this RSU Award, the terms used in this RSU Award shall have the meanings defined in the Plan. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this RSU Award, the terms and conditions of the Plan will prevail.

1.Vesting Schedule.

    (a)    Regular Vesting Schedule. Subject to the acceleration provisions set forth below, 100%of the total Number of Restricted Stock Units subject to this Award shall vest and be settled on the first anniversary of the Date of Grant (the “Settlement Date”); provided that, except as set forth in Section 1(b) below, this Award shall cease vesting immediately upon Participant’s Termination of Service.

        Except as set forth in Section 1(b) below, Restricted Stock Units scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest on such date or occurrence unless Participant has continuously and actively been providing services to the Company from the Date of Grant until the date such vesting occurs. The Administrator (or any delegate) shall have the sole discretion to determine when Participant is no longer employed or providing services for purposes of this Award and participation in the Plan.

        (b)    Accelerated or Special Vesting Conditions

    Subject to the general provisions above, in the event of the following circumstances, the following vesting and settlement provisions shall apply:

(i)    Death. In the event of Participant’s Termination of Service due to Participant’s death, 100% of the Restricted Stock Units subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest immediately and be settled within 60 days following such Termination of Service. The person named in Participant’s will or Participant’s beneficiary, as the case may be, will receive the Shares issued upon settlement of Participant’s Restricted Stock Units, subject to applicable law.

4144-2615-3251.3

(ii)    Disability. In the event of Participant’s Termination of Service due to Participant’s Disability (as defined below), 100% of the Restricted Stock Units subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest immediately and be settled within 60 days following such Termination of Service. For purposes of this Award, “Disability” shall mean that Participant is unable to perform his or her duties as a Director due to disability or incapacity of more than a temporary nature, as determined by the Board of Directors.

(iii)    Termination of Service at Conclusion of Term. In the event of Participant’s Termination of Service at the conclusion of the term for which he or she was elected, 100% of the Restricted Stock Units subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest immediately and be settled within 60 days following such Termination of Service.

    (iv)    Other Termination of Service. In the event of Participant’s Termination of Service before the conclusion of the term for which he or she was elected other than by reason of death, Disability, or a Change in Control, a pro-rata portion of the Restricted Stock Units subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest immediately and be settled within 60 days following such Termination of Service. For this purpose, the pro-rata portion of the Award that vests will be determined based on the number of days that Participant was a Director from the Date of Grant through the date of Participant’s Termination of Service as compared to the total number of days from the Date of Grant to the first anniversary of the Date of Grant. The balance of the Restricted Stock Units that have not vested as of the date of Participant’s Termination of Service and do not vest as a result of Participant’s Termination of Service will be immediately forfeited without consideration. The Company shall have the sole discretion to determine when and under what circumstances Participant’s Termination of Service occurs for purposes of this RSU Award.

    (v)    Change in Control. In the event of a Change in Control while Participant is serving as a Director, 100% of the Restricted Stock Units subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will immediately vest and be settled; provided, however, that if the Change in Control does not qualify as a “change of control” under Section 409A of the Internal Revenue Code of 1986 (“Section 409A”) and this Award constitutes non-exempt deferred compensation within the meaning of Section 409A, settlement of such Restricted Stock Units will instead be made on the normal Settlement Date subject to earlier payout on, the earlier of: (i) the date of Participant’s Termination of Service (within 60 days thereafter), or (ii) the occurrence of a Change in Control which qualifies as a “change of control” under Section 409A.

(vi)    Section 409A. Notwithstanding the foregoing provisions of this Section 1(b), settlement upon Participant’s Termination of Service shall not occur unless such Termination of Service is also a “separation from service” (within the meaning of Section 409A).

2.Company’s Obligation to Pay. Each Restricted Stock Unit represents the right to receive a Share of Common Stock if the Restricted Stock Unit vests. Unless and until the Restricted Stock Units have vested in the manner set forth in Section 1 above, Participant will have no right to payment of any Shares. Prior to actual payment of any Shares, such Restricted Stock Unit will represent an unsecured obligation of the Company. Restricted Stock Units will be automatically settled and paid to Participant in Shares (cash will be paid in lieu of any fractional Shares) upon the Settlement Date (or earlier date for settlement provided in Section 1(b)) of such Restricted Stock Units, subject to Participant satisfying any applicable tax, tax withholding or other obligations as set forth in Section 5 and any other requirements or

-2-

2023 Zoetis Inc. Director RSU Award Agreement

restrictions that may be imposed by the Company to comply with applicable laws or facilitate administration of the Plan.

3.Inappropriate Activity; Clawbacks.

(a)    Forfeiture for Inappropriate Activity. To the extent permitted by applicable law, if at any time Participant engages in any of the activities listed below, this Award (including any vested portion thereof) shall immediately terminate in its entirety and be forfeited without consideration. The activities subject to this paragraph are any activity inimical, contrary or harmful to the interests of the Company or any Affiliate, including, but not limited to: (A) conduct related to Participant’s service as a Director for which either criminal or civil penalties against Participant may be sought, (B) violation of Company or any Affiliate policies, including, without limitation, the Company’s insider trading policy, (C) accepting employment with or serving as a consultant, advisor or in any other capacity to a person or entity that is in competition with or acting against the interest of the Company or any Affiliate while serving as a Director, (D) disclosing or misusing any confidential information or material concerning the Company or any Affiliate, or (E) participating in an attempted hostile takeover of the Company.

(b)    Clawbacks. The Company shall recover all or a portion of any compensation realized by Participant under this Award as defined in and to the extent required by regulations or stock exchange requirements adopted pursuant to the Dodd-Frank Act.

4.Tax Obligations. Regardless of any action the Company takes with respect to any or all applicable national, local, or other taxes or social contributions, withholdings, required deductions, or other payments, if any, that arise upon the grant, vesting or settlement of the Restricted Stock Units or the holding or subsequent sale of Shares, and the receipt of dividends (or dividend equivalent units), if any (“Tax-Related Items”), Participant acknowledges and agrees that the ultimate liability for all Tax-Related Items legally due by Participant is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company. Participant further acknowledges that the Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this RSU Award , including grant, vesting, settlement, the holding or subsequent sale of Shares acquired under the Plan, and the receipt of dividends (or dividend equivalents), if any; and (b) does not commit to and is under no obligation to structure the terms of the Restricted Stock Units or any aspect of the Restricted Stock Units to reduce or eliminate Participant’s liability for Tax-Related Items, or achieve any particular tax result. Further, if Participant has become subject to Tax-Related Items in more than one jurisdiction, Participant acknowledges that the Company may be required to withhold or account for Tax-Related Items in more than one jurisdiction. Notwithstanding any contrary provision of this RSU Award, no Shares will be issued (or other payment made) to Participant, unless and until satisfactory arrangements (as determined by the Administrator) have been made by Participant with respect to the payment of any Tax-Related Items that the Company determines must be satisfied with respect to such Shares.

The Company may require Participant to satisfy applicable tax withholding obligations (if any) by (a) paying cash, (b) having the Company withhold Shares otherwise deliverable to Participant to satisfy the minimum withholding obligation (but only limited to such minimum to the extent required to avoid adverse tax consequences), (c) having the Company withhold the required amount from Participant’s cash compensation or any other payment of any kind otherwise due to Participant,, (d) surrendering already-owned Shares having a Fair Market Value

-3-

2023 Zoetis Inc. Director RSU Award Agreement

equal to the minimum statutory withholding (but only limited to such minimum to the extent required to avoid adverse tax consequences), or (e) pursuant to such other procedures as may be specified by the Administrator from time to time. The Company in its discretion will have the right (but not the obligation) to satisfy any applicable tax withholding obligations by reducing the number of Shares otherwise deliverable to Participant or by withholding such amounts from other compensation payable to Participant. If Participant fails to make satisfactory arrangements for the payment of any applicable tax withholding obligations hereunder at the time any applicable Restricted Stock Units otherwise are scheduled to be settled, Participant will permanently forfeit such Restricted Stock Units and any right to receive Shares thereunder and the Restricted Stock Units will be returned to the Company at no cost to the Company.

5.Rights as Stockholder. Until the issuance of the Shares subject to this Award (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a holder of capital stock shall exist with respect to this Award. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 7 below and Section 3.2 of the Plan

6.Dividend Equivalent Units. Unless otherwise set forth in any applicable Country-Specific Addendum, if the Company declares a cash dividend on its Common Stock, Participant will be entitled to be credited with dividend equivalent units equal to (i) the amount of such dividend declared and paid with respect to one share of Common Stock, multiplied by (ii) the number of Restricted Stock Units subject to this Award plus the number of dividend equivalent units previously credited with respect to such Restricted Stock Units that are outstanding on the applicable dividend record date with respect to such dividend payment date, divided by (iii) the Fair Market Value of a Share of Common Stock on the dividend record date. Dividend equivalent units will not be credited with interest. Each dividend equivalent unit represents one Share of Common Stock and will be paid in Shares at the same time and to the same extent to which the Company issues the Shares underlying the Restricted Stock Units with respect to which they were credited. The Administrator may prospectively change the method of crediting dividend equivalent units as it, in its sole discretion, determines appropriate from time to time.

7.No Guarantee of Continued Service or Grants. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE RESTRICTED STOCK UNITS PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OF RESTRICTED STOCK UNITS OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS RSU AWARD, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE (SUBJECT TO APPLICABLE LAWS).

Participant also acknowledges and agrees that: (a) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time; (b) the grant of Restricted Stock Units is voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units even if Restricted Stock Units have

-4-

2023 Zoetis Inc. Director RSU Award Agreement

been granted repeatedly in the past, and all decisions with respect to future grants of Restricted Stock Units or other Awards, if any, will be at the sole discretion of the Company; (c) all decisions with respect to future awards of Restricted Stock Units, if any, will be at the sole discretion of the Company; (d) Participant’s participation in the Plan is voluntary; (e) the Restricted Stock Units and the Shares subject to the Restricted Stock Units are extraordinary items that do not constitute regular compensation for services rendered to the Company, and are outside the scope of Participant’s service contract, if any; (f) the Restricted Stock Units and the Shares subject to the Restricted Stock Units are not intended to replace any pension rights or compensation; (g) the Restricted Stock Units and the Shares subject to the Restricted Stock Units are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, or end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company.

8.No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant’s participation in the Plan, or Participant’s acquisition or sale of the Shares underlying this Award. Participant is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.

9.Address for Notices. Except as required under Section 15, any notice to be given to the Company under the terms of this RSU Award shall be addressed to the Company, in care of its General Counsel at Zoetis Inc., 10 Sylvan Way, Parsippany, New Jersey, or at such other address as the Company may hereafter designate in writing.

10.Non-Transferability of Restricted Stock Units. The Restricted Stock Units shall not be transferable other than by will or the laws of descent and distribution. The designation of a beneficiary does not constitute a transfer.

11.Binding Agreement. Subject to the limitation on the transferability of this grant contained herein and to the other terms and conditions of the Plan, this RSU Award will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

12.Additional Conditions to Issuance of Shares. If at any time the Company will determine, in its discretion, that the listing, registration or qualification of this Award or the Shares upon any securities exchange or under any state, federal or foreign law, or the consent or approval of any governmental regulatory authority is necessary or desirable as a condition to the grant of this Award or the issuance of Shares to Participant (or his or her beneficiary or estate), such grant or issuance will not occur unless and until such listing, registration, qualification, consent or approval will have been effected or obtained free of any conditions not acceptable to the Company. Where the Company determines that the grant of this Award or the delivery of the payment of any Shares will violate federal securities laws or other applicable laws, the Company will defer the grant of this Award or the delivery of the Shares until the earliest date at which the Company reasonably anticipates that the grant of this Award or the delivery of Shares will no longer cause such violation. The Company shall have no obligation, and will have no liability

-5-

2023 Zoetis Inc. Director RSU Award Agreement

for failure, to satisfy the requirements of any such state, federal or foreign law or securities exchange or to obtain any such consent or approval of any such governmental authority. The Company shall not be obligated to treat this Award as outstanding or issue any Shares pursuant to this Award at any time if the grant of this Award or the issuance of Shares pursuant to this Award violates or is not in compliance with any laws, rules or regulations of the United States or any state or country.

Furthermore, the Company reserves the right to impose other requirements on Participant’s participation in the Plan, this Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with applicable law or facilitate the administration of the Plan, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Furthermore, Participant understands that the laws of the country in which he or she is resident at the time of grant or vesting or settlement of this Award or the holding or disposition of Shares or receipt of dividends (or dividend equivalent units), if any (including any rules or regulations governing securities, foreign exchange, tax, labor or other matters) may restrict or prevent the grant of this Award or the issuance of Shares or may subject Participant to additional procedural or regulatory requirements he or she is solely responsible for and will have to independently fulfill in relation to this Award or the Shares. Notwithstanding any provision herein, this Award and any Shares issuable hereunder shall be subject to any special terms and conditions or disclosures as set forth in any addendum for Participant’s country (the “Country-Specific Addendum”), which forms part this RSU Award.

13.Administrator Authority. The Administrator has the power to interpret the Plan and this RSU Award and to adopt such rules for the administration, interpretation and application of the Plan and this RSU Award as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Restricted Stock Units have vested). All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons. No member of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this RSU Award.

14.Electronic Delivery and Language. The Company may, in its sole discretion, decide to deliver any documents related to this Award, any future restricted stock units or other equity awards granted by the Company, whether under the Plan or otherwise, or any other Company securities by electronic means or request Participant’s consent to participate in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company. If Participant has received this RSU Award, including appendices, or any other document related to the Plan translated into a language other than English, and the meaning of the translated version is different than the English version, the English version will control.

15.Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this RSU Award.

-6-

2023 Zoetis Inc. Director RSU Award Agreement

16.Severability. In the event that any provision in this RSU Award will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this RSU Award.

17.Modifications to the RSU Award and the Plan.

(a)    This RSU Award and the Plan constitute the entire understanding of the parties on the subjects covered. Participant expressly warrants that he or she is not accepting this Award in reliance on any promises, representations, or inducements other than those contained herein.

(b)    In the event of a Change in Capitalization (as defined in Section 3.2 of the Plan), the Administrator shall make equitable adjustments to this Award as provided in Section 3.2 of the Plan. Except as provided in the preceding sentence, modifications to this Award can be made only in an express written contract executed by a duly authorized officer of the Company.

(c)    The Administrator expressly reserves the right to terminate this RSU Award prior to the Settlement Date, in which case the number of Restricted Stock Units and related dividend equivalent units shall be calculated as if the Settlement Date was the trading day immediately prior to the date of such termination (without proration to reflect the shortened vesting period), and shall be settled immediately; provided, however, that if immediate settlement is not permitted under Section 409A of the Code, such Restricted Stock Units and related dividend equivalent units shall be converted to cash based on the Fair Market Value of a Share of Common Stock on the date of termination of the Award and such amount shall be paid to Participant at the earliest date permitted under Section 409A of the Code.

(d)    Notwithstanding anything to the contrary in the Plan or this RSU Award, the Company reserves the right to revise this RSU Award as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Section 409A of the Code or to otherwise avoid imposition of any additional tax or income recognition under Section 409A of the Code in connection with this RSU Award.

(e)    Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time, subject to the terms of the Plan.

18.Data Privacy. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant’s Personal Data (as described below) by and among, as applicable, the Company, any of its Affiliates, and third parties as may be selected by the Company, for the exclusive purpose of implementing, administering and managing Participant’s participation in the Plan. Participant understands that refusal or withdrawal of consent will affect Participant’s ability to participate in the Plan; without providing consent, Participant will not be able to participate in the Plan or realize benefits (if any) from this Award.

-7-

2023 Zoetis Inc. Director RSU Award Agreement

Participant understands that the Company and its Affiliates and any designated third parties may hold certain personal information about Participant, including, but not limited to, Participant’s name, home address and telephone number, date of birth, social insurance number or other identification number, compensation, nationality, job title, any shares of stock or directorships held in the Company or any Affiliate, details of all Restricted Stock Units, Shares, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant’s favor, for the exclusive purpose of implementing, administering and managing the Plan (“Personal Data”). Participant understands that Personal Data may be transferred to any Affiliates or third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the United States, Participant’s country (if different than the United States), or elsewhere, and that the recipient’s country may have different data privacy laws and protections than Participant’s country. In particular, the Company may transfer Personal Data to the broker or stock plan administrator assisting with the Plan, to its legal counsel and tax/accounting advisor, and to the Subsidiary or Affiliate and its payroll provider.

Participant should also refer to the Zoetis Privacy Policy (which is available to Participant separately and may be updated from time to time) for more information regarding the collection, use, storage, and transfer of Participant’s Personal Data.

19.Foreign Exchange Fluctuations and Restrictions. Participant understands and agrees that the future value of the underlying Shares is unknown and cannot be predicted with certainty and may decrease. Participant also understands that neither the Company, nor any Affiliate is responsible for any foreign exchange fluctuation between local currency and the United States Dollar or the selection by the Company or any Affiliate in its sole discretion of an applicable foreign currency exchange rate that may affect the value of the Restricted Stock Units or Shares received (or the calculation of income or Tax-Related Items thereunder). Participant understands and agrees that any cross-border remittance made to transfer proceeds received upon the sale of Shares must be made through a locally authorized financial institution or registered foreign exchange agency and may require the Participant to provide such entity with certain information regarding the transaction.

20.Governing Law. This RSU Award will be governed by the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this RSU Award or the Plan, the parties hereby submit to and consent to the jurisdiction of the State of New Jersey and agree that such litigation will be conducted in the state courts of Morris County, New Jersey, or the federal courts of the United States for the District of New Jersey, and no other courts.

21.Acceptance of Award. By Participant’s acceptance of this RSU Award, Participant and the Company agree that this Award of Restricted Stock Units is granted under and governed by the terms and conditions of this RSU Award (including any Country-Specific Addendum hereto) and the Plan, and any ancillary documents, all of which are being delivered simultaneously with, and made a part of, this RSU Award. In addition, Participant acknowledges and agrees that Participant has reviewed the Plan and this RSU Award in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this RSU Award and fully understands all provisions of the Plan and this RSU Award. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and this RSU Award. Participant further agrees to notify the Company upon any change in Participant’s residence address.

-8-

2023 Zoetis Inc. Director RSU Award Agreement

-9-

2023 Zoetis Inc. Director RSU Award Agreement

EX-10.2

Exhibit 10.2

ZOETIS INC.

2013 EQUITY AND INCENTIVE PLAN

CASH RESTRICTED STOCK UNIT AWARD

Zoetis Inc. (the “Company”) has granted to the person named below (the “Participant”), a cash restricted stock unit award (“Cash RSU Award”), subject to all of the terms, definitions and provisions of this Cash RSU Award and the Zoetis Inc. 2013 Equity and Incentive Plan, as amended and restated (the “Plan”), which is incorporated herein by reference, as follows:

Participant Name        

Date of Grant        

Number of Underlying Shares         

Unless otherwise defined in this Cash RSU Award, the terms used in this Cash RSU Award shall have the meanings defined in the Plan. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Cash RSU Award, the terms and conditions of the Plan will prevail.

1.Vesting Schedule.

    (a)    Regular Vesting Schedule. Subject to any acceleration provisions contained in the Plan or set forth below, one-third of the Cash RSU Awards subject to this award shall vest and be settled on the first, second and third anniversaries of the Date of Grant (the “Settlement Dates”); provided that, except as set forth in Section 1(b) below, this Award shall cease vesting immediately upon Participant’s Termination of Service.

Except as set forth in Section 1(b) below, Cash RSU Awards scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest on such date or occurrence unless Participant has continuously and actively been employed with, or providing services to, the Company or any of its Subsidiaries or Affiliates from the Date of Grant until the date such vesting occurs. For non-U.S. Participants and for purposes of this Award only, except as determined by the Administrator (or any delegate) in its sole discretion, Termination of Service will be deemed to be as of the date that Participant is no longer actively providing services and will not be extended by any notice period or “garden leave” that may be required contractually or under applicable law. For U.S. Participants and for purposes of this Award only, such Participants shall be deemed to be continuously and actively employed with, or providing services to, the Company or any of its Subsidiaries or Affiliates during any notification period required by the Worker Adjustment and Retraining Notification Act of 1988 (or any analogous state law) or during any such other period determined by the Administrator (or any delegate) in its sole discretion. Notwithstanding the foregoing, the Administrator (or any delegate) shall have the sole discretion to determine when Participant is no longer employed or providing services for purposes of this Award and participation in the Plan.

        (b)    Accelerated or Special Vesting Conditions. Subject to the general provisions above, in the event of the following circumstances, the following vesting and settlement provisions shall apply:

4125-8275-9715.3

(i)    Death. In the event of Participant’s Termination of Service due to Participant’s death, 100% of the Cash RSU Awards subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest and be settled immediately upon such termination. The person named in Participant’s will or Participant’s beneficiary, as the case may be, will receive payment upon settlement of Participant’s Cash RSU Award, subject to applicable law.

(ii)    Total and Permanent Disability. In the event of Participant’s Termination of Service due to Participant’s Total and Permanent Disability (as defined below), 100% of the Cash RSU Awards subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest and be settled immediately upon such termination. For purposes of this Award, “Total and Permanent Disability” shall mean that Participant is receiving long-term disability benefits under the Company’s long-term disability program.

(iii)    Retirement. In the event of Participant’s Termination of Service due to Participant’s Retirement (as defined below) on or after the first anniversary of the Date of Grant, a pro-rata portion of the Cash RSU Awards subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest and be settled immediately upon such Termination of Service. For this purpose, the pro-rata portion of the Award that vests will be determined based on the number of days that Participant was an active Employee from the Date of Grant through the date of Participant’s Termination of Service as compared to the total number of days from the Date of Grant to the third anniversary of the Date of Grant, less the portion of the Award that has already vested. For purposes of this Award, “Retirement” means Participant has attained a minimum of sixty-five (65) combined years of age and service with the Company or any Affiliate and a minimum age of fifty-five (55).

    (iv)    Termination as a Result of a Plant Closing or Restructuring Event. In the event of Participant’s Termination of Service as a result of a plant closing or Restructuring Event (as defined below), a pro-rata portion of the Cash RSU Awards subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below) will vest and be settled immediately upon such Termination of Service. For this purpose, the pro-rata portion of the Award that vests will be determined based on the number of days that Participant was an active Employee from the Date of Grant through the date of Participant’s Termination of Service as compared to the total number of days from the Date of Grant to the third anniversary of the Date of Grant, less the portion of the Award that has already vested. For purposes of this Award, a “Restructuring Event” means an involuntary Termination of Service without Cause and not related to performance, that is the direct result of (i) a “restructuring event” as determined for financial statement reporting purposes, (ii) a divestiture or sale of a site or a business/business unit of the Company or its Affiliates, or (iii) a position elimination or a job restructuring including, but not limited to, a change in required competencies or qualifications for a position, as determined by the Plan Administrator, in its sole discretion.

    (v)    Termination without Cause or Resignation for Good Reason following a Change in Control. In the event of Participant’s Termination of Service by the Company or an Affiliate without Cause (as defined below) or as a result of Participant’s resignation for Good Reason (as defined below), in either case, upon or within twenty-four (24) months following the consummation of a Change in Control, 100% of the Cash RSU Awards subject to this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 below), as assumed or substituted by the acquiring company and adjusted to reflect the transaction if applicable will immediately vest and be settled upon such termination.

-2-

2023 Zoetis Inc. Cash RSU Award Agreement

    For purposes of this Award, “Cause” means (i) an act of dishonesty, fraud or misrepresentation made by Participant in connection with Participant’s responsibilities to the Company, (ii) Participant’s willful, material violation of any law or regulation applicable to the business of the Company; (iii) Participant’s conviction of, or plea of nolocontendere to, a felony or any crime that, in either case, has resulted in or is reasonably expected to result in material injury to the business or reputation of the Company, (iv) Participant’s willful misconduct or gross negligence in connection with carrying out Participant’s job responsibilities to the Company, (v) Participant’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Participant owes an obligation of nondisclosure as a result of Participant’s relationship with the Company; (vi) Participant’s willful breach of any obligations under any written agreement or covenant with the Company that is injurious to the Company; (vii) Participant’s violation or disregard of any Company policy that has resulted in or is reasonably expected to result in material injury to the business or reputation of the Company; or (viii) Participant’s failure or refusal to perform Participant’s duties and responsibilities to the Company. For purposes of clarity, all references herein to the Company shall include references to any Affiliate and any successor to the Company or any Affiliate, and a termination without “Cause” does not include any termination that occurs as a result of Participant’s death or disability.

    For purposes of this Award, “Good Reason” means Participant’s resignation due to the occurrence of any of the following conditions which occurs without Participant’s written consent, provided that the requirements regarding advance notice and an opportunity to cure set forth below are satisfied: (i) a material reduction of Participant’s base compensation (other than as part of an across-the-board salary reduction applicable to all similarly situated employees); (ii) a material reduction of Participant’s duties, authority, responsibilities or reporting relationship, relative to Participant’s duties, authority, responsibilities or reporting relationship as in effect immediately prior to such reduction; or (iii) the Company (or a successor, if appropriate) requires Participant to relocate to a facility or location more than twenty-five (25) miles away from the location at which Participant was working immediately prior to the required relocation and such relocation increases Participant’s one way commute by thirty (30) minutes or more during normal commuting hours and under typical traffic conditions.  In order for Participant to resign for Good Reason, Participant must provide written notice to the Company of the existence of the Good Reason condition within sixty (60) days of the initial existence of such Good Reason condition. Upon receipt of such notice, the Company will have thirty (30) days during which it may remedy the Good Reason condition. If the Good Reason condition is not remedied within such thirty (30) day period, Participant may resign based on the Good Reason condition specified in the notice effective no later than thirty (30) days following the expiration of the Company’s thirty (30) day cure period.

    (vi)    Delay for Key Employees. Notwithstanding the foregoing provisions of this Section 1(b), if Participant is a Key Employee (as determined pursuant to the definition of the term “Key Employee” in the Zoetis Supplemental Savings Plan), any amounts which constitute “deferred compensation” under Internal Revenue Code Section 409A payable in connection with Participant’s Termination of Service shall not be paid upon such Participant’s Termination of Service, but instead shall be paid on the day that is six months following such Participant’s Termination of Service, or upon Participant’s death, if earlier.

2.Company’s Obligation to Pay. This Cash RSU Award, to the extent vested, represents the right to receive, for each underlying Share subject to this Award (as set forth on page 1 hereof) a cash lump sum payment equal to the Fair Market Value of a Share on the vesting date. No Shares shall be issued to Participant with respect to the Cash RSU Award. Unless and until the Cash RSU Award has vested in the manner set forth in Section 1 above, Participant will have no right to payment under this Cash RSU Award. Prior to actual payment of this Award, this Cash RSU Award will represent an unsecured obligation of the Company,

-3-

2023 Zoetis Inc. Cash RSU Award Agreement

payable (if at all) only from the general assets of the Company. The Cash RSU Award will be automatically settled and paid to Participant in cash in a lump sum upon the Settlement Date ((or earlier date for settlement as provided in Section 1(b)) of this Cash RSU Award, net of all applicable Tax-Related Items (as defined in Section 5 below) and subject to Participant satisfying any other requirements or restrictions that may be imposed by the Company to comply with applicable laws or facilitate administration of the Plan. Payment of this Cash RSU Award shall be made through local payroll.

3.Forfeiture upon Termination of Service. Subject to Section 1(b) hereof, in the event of Participant’s Termination of Service for any or no reason, the vesting of the Cash RSU Award will immediately cease and the balance of the Cash RSU Award that has not vested as of the date of Participant’s Termination of Service and does not vest as a result of Participant’s Termination of Service will be immediately forfeited without consideration. The Company shall have the sole discretion to determine when and under what circumstances Participant’s Termination of Service occurs for purposes of this Cash RSU Award.

4.Inappropriate Activity; Clawbacks.

(a)    Forfeiture for Inappropriate Activity. If at any time Participant engages in any of the activities listed below, this Award (including any vested portion thereof) shall immediately terminate in its entirety and be forfeited without consideration, subject to applicable law. The activities subject to this paragraph are any activity inimical, contrary or harmful to the interests of the Company or any Affiliate, including, but not limited to: (A) conduct related to Participant’s employment for which either criminal or civil penalties against Participant may be sought, (B) violation of Company or any Affiliate policies, including, without limitation, the Company’s insider trading policy, (C) accepting employment with or serving as a consultant, advisor or in any other capacity to a person or entity that is in competition with or acting against the interest of the Company or any Affiliate while employed by the Company or an Affiliate, and, for senior leaders (global job level 110 or above), within one year following a termination of employment for any reason1, (D) disclosing or misusing any confidential information or material concerning the Company or any Affiliate, or (E) participating in an attempted hostile takeover of the Company.

(b)    Clawbacks. Subject to applicable law, (A) if either the grant or the compensation realized under this Award was based on the achievement of financial results that were subsequently materially restated (other than a restatement due to a change in accounting principles) and such restatement caused the Company to reissue previously audited financial statements and the related audit opinions, (B) if Participant was determined to have altered the financial or operational results used to determine the amount earned under any Award under the Plan through fraud or material misconduct, (C) if Participant’s willful misconduct or gross negligence in connection with carrying out Participant’s job responsibilities to the Company has or might reasonably be expected to have significant business or reputational harm to the Company or any Affiliate, or (D) if Participant violates section 4 (a) (C) of this agreement, then (i) any compensation realized by Participant under this Award within three years prior to the date of such financial restatement, determination of financial misconduct or violation of section 4 (a) (C) of this agreement shall be recoverable by the Company, and (ii) all unpaid portions of this Award (whether or not vested) shall be cancelled and forfeited. In addition, with respect to circumstances or time periods not covered by the preceding sentence, the Company shall recover all or a portion of any compensation realized by Participant under this Award as defined in and to

1 Not applicable to Participants employed by the Company or its Affiliates in the state of California or Oklahoma in the United States

-4-

2023 Zoetis Inc. Cash RSU Award Agreement

the extent required by regulations or stock exchange requirements adopted pursuant to the Dodd-Frank Act, subject to applicable law.

5.Tax Obligations. Regardless of any action the Company or Participant’s employer (the “Employer”) takes with respect to any or all applicable national, local, or other taxes or social contributions, withholdings, required deductions, or other payments, if any, that arise upon the grant, vesting, or settlement of the Cash RSU Award, including dividend equivalents with respect thereto credited pursuant to Section 7 below, (“Tax-Related Items”), Participant acknowledges and agrees that the ultimate liability for all Tax-Related Items legally due by Participant is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant agrees to make adequate provision for (and indemnify the Company and any Subsidiary or Affiliate for) any Tax-Related Items. Participant further acknowledges and agrees that Participant is solely responsible for filing all relevant documentation that may be required in relation to this Award or any Tax-Related Items other than filings or documentation that is the specific obligation of the Company or any Subsidiary or Affiliate pursuant to applicable law, such as but not limited to personal income tax returns or reporting statements in relation to the grant, vesting, or settlement of this Award, or any bank account. Participant further acknowledges that the Company and the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Cash RSU Award, including grant, vesting, or settlement; and (b) do not commit to and are under no obligation to structure the terms of the Cash RSU Award or any aspect of the Cash RSU Award to reduce or eliminate Participant’s liability for Tax-Related Items, or achieve any particular tax result. Participant also understands that applicable laws may require varying Share valuation methods for purposes of calculating Tax-Related Items, and the Company assumes no responsibility or liability in relation to any such valuation.  The Company is also not responsible or liable for any calculation or reporting of income or Tax-Related Items that may be required of Participant under applicable laws. Further, if Participant has become subject to Tax-Related Items in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction. In addition, the Company may require Participant to satisfy applicable tax withholding obligations by having the Company or the Employer withhold the required amount from Participant’s wages or other cash compensation or any other payment of any kind otherwise due to Participant, subject to applicable law.

6.No Rights as Stockholder. No right to vote or receive dividends or any other rights as a holder of capital stock shall exist with respect to this Award. No adjustment will be made, except as provided in Section 3.2 of the Plan.

7.Dividend Equivalent Units. If the Company declares a cash dividend on its Common Stock, Participant will be entitled to be credited with dividend equivalent units equal to (i) the amount of such dividend declared and paid with respect to one share of Common Stock, multiplied by (ii) the number of underlying Shares subject to this Award (as set forth on page 1 herein) subject to this Award plus the number of dividend equivalent units previously credited with respect to such underlying Shares subject to this Award (as set forth on page 1 herein) that are outstanding on the applicable dividend record date with respect to such dividend payment date, divided by (iii) the Fair Market Value of a Share of Common Stock on the dividend record date. Dividend equivalent units will not be credited with interest. Each dividend equivalent unit represents a cash payment equal to one Share of Common Stock and will be paid in cash at the same time and to the same extent to which the Company makes a cash lump sum payment underlying the Cash RSU Award with respect to which they were credited. The Administrator may prospectively change the method of crediting dividend equivalent units as it, in its sole discretion, determines appropriate from time to time.

-5-

2023 Zoetis Inc. Cash RSU Award Agreement

8.No Guarantee of Continued Service or Grants. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE CASH RSU AWARD PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE EMPLOYER) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS CASH RSU AWARD OR RECEIVING PAYMENT HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS CASH RSU AWARD, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE EMPLOYER) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE (SUBJECT TO APPLICABLE LAWS).

Participant also acknowledges and agrees that: (a) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time; (b) the grant of Cash RSU Awards is voluntary and occasional and does not create any contractual or other right to receive future grants of Cash RSU Awards, or benefits in lieu of Cash RSU Awards even if Cash RSU Awards have been granted repeatedly in the past, and all decisions with respect to future grants of Cash RSU Awards or other Awards, if any, will be at the sole discretion of the Company; (c) all decisions with respect to future awards of Cash RSU Awards, if any, will be at the sole discretion of the Company; (d) Participant’s participation in the Plan is voluntary; (e) the Cash RSU Awards and the cash payments subject to the Cash RSU Awards are extraordinary items that do not constitute regular compensation for services rendered to the Company or the Employer, and that are outside the scope of Participant’s employment contract, if any; (f) the Cash RSU Awards and the cash payments subject to the Cash RSU Awards are not intended to replace any pension rights or compensation; (g) the Cash RSU Awards and the cash payments subject to the Cash RSU Awards are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, or end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or the Employer.

9.No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant’s participation in the Plan. Participant is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.

10.Address for Notices. Except as required under Section 14, any notice to be given to the Company under the terms of this Cash RSU Award shall be addressed to the Company, in care of its General Counsel at Zoetis Inc., 10 Sylvan Way, Parsippany, New Jersey 07054, or at such other address as the Company may hereafter designate in writing.

11.Non-Transferability of Cash RSU Award. The Cash RSU Award shall not be transferable other than by will or the laws of descent and distribution. The designation of a beneficiary does not constitute a transfer.

-6-

2023 Zoetis Inc. Cash RSU Award Agreement

12.Binding Agreement. Subject to the limitation on the transferability of this grant contained herein and to the other terms and conditions of the Plan, this Cash RSU Award will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

13.Additional Conditions to Payment. If at any time the Company will determine, in its discretion, that any additional steps or qualification in relation to this Award under any state, federal or foreign law or the consent or approval of any governmental regulatory authority is necessary or desirable as a condition to the grant of this Award or payment thereunder to Participant (or his or her estate), such grant or payment will not occur unless and until such steps, qualification, consent or approval will have been effected or obtained free of any conditions not acceptable to the Company. Where the Company determines that the grant of this Award or the delivery of the payment will violate any applicable laws, the Company will defer the grant of this Award or the delivery of payment until the earliest date at which the Company reasonably anticipates that the grant of this Award or the delivery of payment will no longer cause such violation. The Company shall have no obligation to satisfy the requirements of any such state, federal or foreign law or to obtain any such consent or approval of any such governmental authority. The Company shall not be obligated to treat this Award as outstanding or make any payment pursuant to this Award at any time if the grant of this Award or payment pursuant to this Award violates or is not in compliance with any laws, rules or regulations of the United States or any state or country.

Furthermore, the Company reserves the right to impose other requirements on Participant’s participation in the Plan, this Award and on any payment made under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with applicable law or facilitate the administration of the Plan, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Furthermore, Participant understands that the laws of the country in which he or she is resident at the time of grant or vesting or settlement of the this Award (including dividend equivalents with respect thereto credited pursuant to Section 7 above), if any (including any rules or regulations governing securities, foreign exchange, tax, labor or other matters) may restrict or prevent the grant of this Award or the payment thereunder or may subject Participant to additional procedural or regulatory requirements he or she is solely responsible for and will have to independently fulfill in relation to this Award.

14.Administrator Authority. The Administrator will have the power to interpret the Plan and this Cash RSU Award and to adopt such rules for the administration, interpretation and application of the Plan and this Cash RSU Award as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any portion of the Cash RSU Award has vested). All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons. No member of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Cash RSU Award.

15.Electronic Delivery and Language. The Company may, in its sole discretion, decide to deliver any documents related to this Award, any future Cash RSU Awards or other

-7-

2023 Zoetis Inc. Cash RSU Award Agreement

awards granted by the Company, whether under the Plan or otherwise, or any Company securities by electronic means. By accepting this Award, whether electronically or otherwise, Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company, including but not limited to the use of electronic signatures or click-through electronic acceptance or terms and conditions. If Participant has received this Cash RSU Award or any other document related to the Plan translated into a language other than English, and the meaning of the translated version is different than the English version, the English version will control.

16.Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Cash RSU Award.

17.Severability. In the event that any provision in this Cash RSU Award will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Cash RSU Award.

18.Modifications to the Cash RSU Award and the Plan.

(a)    This Cash RSU Award and the Plan constitutes the entire understanding of the parties on the subjects covered. Participant expressly warrants that he or she is not accepting this Cash RSU Award in reliance on any promises, representations, or inducements other than those contained herein.

(b)    In the event of a Change in Capitalization (as defined in Section 3.2 of the Plan), the Administrator shall make equitable adjustments to this Award as provided in Section 3.2 of the Plan. Except as provided in the preceding sentence, modifications to this Cash RSU Award can be made only in an express written contract executed by a duly authorized officer of the Company.

(c)    The Administrator expressly reserves the right to terminate this Cash RSU Award prior to the Settlement Date, in which case the Fair Market Value of the underlying Shares subject to this Cash RSU Award and related dividend equivalent units shall be calculated as if the Settlement Date was the trading day immediately prior to the date of such termination (without proration to reflect the shortened vesting period), and shall be settled immediately, provided, however, that if immediate settlement is not permitted under Section 409A of the Code, payment with respect to this Cash RSU Award and related dividend equivalent units shall be paid to Participant at the earliest date permitted under Section 409A of the Code.

(d)    Notwithstanding anything to the contrary in the Plan or this Cash RSU Award, the Company reserves the right to revise this Cash RSU Award as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Section 409A of the Code or to otherwise avoid imposition of any additional tax or income recognition under Section 409A of the Code in connection with this Cash RSU Award.

(e)    Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time, subject to the terms of the Plan.

19.Data Privacy. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant’s Personal Data (as

-8-

2023 Zoetis Inc. Cash RSU Award Agreement

described below) by and among, as applicable, the Company, any of its Affiliates, and third parties as may be selected by the Company, for the exclusive purpose of implementing, administering and managing Participant’s participation in the Plan. Participant understands that refusal or withdrawal of consent will affect Participant’s ability to participate in the Plan; without providing consent, Participant will not be able to participate in the Plan or realize benefits (if any) from this Award.

Participant understands that the Company and its Affiliates and any designated third parties may hold certain personal information about Participant, including, but not limited to, Participant’s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company or any Affiliate, details of all Cash RSU Awards, Shares, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant’s favor, for the exclusive purpose of implementing, administering and managing the Plan (“Personal Data”). Participant understands that Personal Data may be transferred to any Affiliates or third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the United States, Participant’s country (if different than the United States), or elsewhere, and that the recipient’s country may have different data privacy laws and protections than Participant’s country. In particular, the Company may transfer Personal Data to the broker or stock plan administrator assisting with the Plan, to its legal counsel and tax/accounting advisor, and to the Subsidiary or Affiliate that is Participant’s Employer and its payroll provider.

Participant should also refer to the Zoetis Employee Privacy Policy (which is available to Participant separately and may be updated from time to time) for more information regarding the collection, use, storage, and transfer of Participant’s Personal Data.

20.Foreign Exchange Fluctuations and Restrictions. Participant understands and agrees that the future value of Shares is unknown and cannot be predicted with certainty and may decrease. Participant also understands that neither the Company, nor any Affiliate is responsible for any foreign exchange fluctuation between local currency and the United States Dollar or the selection by the Company or any Affiliate in its sole discretion of an applicable foreign currency exchange rate that may affect the value of the Cash RSU Award or payment received (or the calculation of income or Tax-Related Items thereunder).

21.Governing Law. This Cash RSU Award will be governed by the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this Cash RSU Award or the Plan, the parties hereby submit to and consent to the jurisdiction of the State of New Jersey and agree that such litigation will be conducted in the state courts of Morris County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts.

21.    Acceptance of Award. By Participant’s acceptance of this Cash RSU Award, Participant and the Company agree that this Cash RSU Award is granted under and governed by the terms and conditions of this Cash RSU Award and the Plan, and any ancillary documents, all of which are being delivered simultaneously with, and made a part of, this Cash RSU Award. In addition, Participant acknowledges and agrees that Participant has reviewed the Plan and this Cash RSU Award in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Cash RSU Award and fully understand all provisions of the Plan and this Cash RSU Award. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and this Cash RSU

-9-

2023 Zoetis Inc. Cash RSU Award Agreement

Award. Participant further agrees to notify the Company upon any change in Participant’s residence address.

-10-

2023 Zoetis Inc. Cash RSU Award Agreement

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kristin C. Peck, certify that:

1.    I have reviewed this Quarterly Report of Zoetis Inc. on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 4, 2023	By:	/s/ KRISTIN C. PECK
		Kristin C. Peck
		Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Wetteny Joseph, certify that:

1.    I have reviewed this Quarterly Report of Zoetis Inc. on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 4, 2023	By:	/s/ WETTENY JOSEPH
		Wetteny Joseph
		Executive Vice President and Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. §1350, I, Kristin C. Peck, Chief Executive Officer, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Zoetis Inc. for the period ended March 31, 2023 (the "Report") (1) fully complies with Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Zoetis Inc.

May 4, 2023	By:	/s/ KRISTIN C. PECK
		Kristin C. Peck
		Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. §1350, I, Wetteny Joseph, Executive Vice President and Chief Financial Officer, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Zoetis Inc. for the period ended March 31, 2023 (the “Report”) (1) fully complies with Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Zoetis Inc.

May 4, 2023	By:	/s/ WETTENY JOSEPH
		Wetteny Joseph
		Executive Vice President and Chief Financial Officer

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-35797
Entity Registrant Name	Zoetis Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-0696167
Entity Address, Address Line One	10 Sylvan Way,
Entity Address, City or Town	Parsippany,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	973
Local Phone Number	822-7000
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ZTS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		462,112,140
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001555280
Current Fiscal Year End Date	--12-31

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue		$ 2,000	$ 1,986
Costs and expenses:
Cost of sales		588	569
Selling, general and administrative expenses		505	465
Research and development expenses		142	122
Amortization of intangible assets		37	41
Restructuring charges and certain acquisition-related costs		21	2
Interest expense, net of capitalized interest		63	53
Other (income)/deductions—net		(53)	7
Income before provision for taxes on income	[1]	697	727
Provision for taxes on income		146	133
Net income before allocation to noncontrolling interests		551	594
Less: Net loss attributable to noncontrolling interests		(1)	(1)
Net income attributable to Zoetis Inc.		$ 552	$ 595
Earnings per share attributable to Zoetis Inc. stockholders:
Basic (in dollars per share)		$ 1.19	$ 1.26
Diluted (in dollars per share)		$ 1.19	$ 1.26
Weighted-average common shares outstanding:
Basic (in shares)		463.5	472.2
Diluted (in shares)		464.6	474.1
Dividends paid per common share (in dollars per share)		$ 0.375	$ 0.325

[1] Defined as income before provision for taxes on income.

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Net income before allocation to noncontrolling interests		$ 551	$ 594
Other comprehensive (loss)/income, net of tax(a):
Foreign currency translation adjustments	[1]	(7)	21
Benefit plans: Actuarial gain, net of tax of $1 and $0 for the three months ended March 31, 2023 and 2022, respectively	[1]	4	1
Other comprehensive (loss)/income, net of tax		(11)	60
Comprehensive income before allocation to noncontrolling interests		540	654
Less: Comprehensive loss attributable to noncontrolling interests		(1)	(1)
Comprehensive income attributable to Zoetis Inc.		541	655
Cash Flow Hedging
Other comprehensive (loss)/income, net of tax(a):
Unrealized gains on derivatives for cash flow hedges, net and net investment hedges	[1]	(2)	26
Net Investment Hedging
Other comprehensive (loss)/income, net of tax(a):
Unrealized gains on derivatives for cash flow hedges, net and net investment hedges	[1]	$ (6)	$ 12

[1] Presented net of reclassification adjustments, which are not material in any period presented.

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax	$ 1,000	$ 0
Cash Flow Hedging
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	(1,000)	7,000
Net Investment Hedging
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	$ (2,000)	$ 4,000

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions		Mar. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	[1]	$ 2,109	$ 3,581
Accounts receivable, less allowance for doubtful accounts of $20 in 2023 and $19 in 2022		1,186	1,215
Inventories		2,563	2,345
Other current assets		411	365
Total current assets		6,269	7,506
Property, plant and equipment, less accumulated depreciation of $2,374 in 2023 and $2,297 in 2022		2,913	2,753
Operating lease right of use assets		216	220
Goodwill		2,738	2,746
Identifiable intangible assets, less accumulated amortization		1,314	1,380
Noncurrent deferred tax assets		161	173
Other noncurrent assets		143	147
Total assets		13,754	14,925
Liabilities and Equity
Short-term borrowings		3	2
Current portion of long-term debt		0	1,350
Accounts payable		424	405
Dividends payable		174	174
Accrued expenses		701	682
Accrued compensation and related items		232	300
Income taxes payable		277	157
Other current liabilities		104	97
Total current liabilities		1,915	3,167
Long-term debt, net of discount and issuance costs		6,559	6,552
Noncurrent deferred tax liabilities		131	142
Operating lease liabilities		180	186
Other taxes payable		262	258
Other noncurrent liabilities		216	217
Total liabilities		9,263	10,522
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 462,495,343 and 463,808,059 shares outstanding at March 31, 2023, and December 31, 2022, respectively		5	5
Treasury stock, at cost, 39,395,900 and 38,083,184 shares of common stock at March 31, 2023 and December 31, 2022, respectively		(4,807)	(4,539)
Additional paid-in capital		1,079	1,088
Retained earnings		9,045	8,668
Accumulated other comprehensive loss		(828)	(817)
Total Zoetis Inc. equity		4,494	4,405
Noncontrolling interests		(3)	(2)
Total equity		4,491	4,403
Total liabilities and equity		$ 13,754	$ 14,925

[1] As of March 31, 2023 and December 31, 2022, includes $4 million of restricted cash.

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 20	$ 19
Accumulated depreciation	$ 2,374	$ 2,297
Common stock, par value (in dollars per share)	$ 0.01
Common stock, shares authorized	6,000,000,000
Common stock issued, shares	501,891,243	501,891,243
Common stock, shares outstanding	462,495,343	463,808,059
Treasury stock, shares	39,395,900	38,083,184
Restricted cash	$ 4	$ 4

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total	Common Stock	Treasury Stock	Treasury Stock Share Repurchase Program	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021			501,900,000
Beginning balance at Dec. 31, 2021		$ 4,544	$ 5	$ (2,952)		$ 1,068	$ 7,186	$ (764)	$ 1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		594					595		(1)
Other comprehensive (loss)/income, net of tax		60						60
Treasury stock, beginning balance (in shares) at Dec. 31, 2021				29,300,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares				(1,900,000)	(500,000)
Share-based compensation awards		(27)		$ (4)		(23)	0
Treasury stock acquired		(361)		(361)
Employee benefit plan contribution from Pfizer Inc.	[1]	1				1
Dividends, Common Stock		(153)					(153)
Ending balance (in shares) at Mar. 31, 2022			501,900,000
Ending balance at Mar. 31, 2022		$ 4,658	$ 5	$ (3,317)		1,046	7,628	(704)	0
Treasury stock, ending balance (in shares) at Mar. 31, 2022				30,700,000
Beginning balance (in shares) at Dec. 31, 2022		501,891,243	501,900,000
Beginning balance at Dec. 31, 2022		$ 4,403	$ 5	$ (4,539)		1,088	8,668	(817)	(2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		551					552		(1)
Other comprehensive (loss)/income, net of tax		$ (11)						(11)
Treasury stock, beginning balance (in shares) at Dec. 31, 2022		38,083,184		38,100,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares				(1,700,000)	(400,000)
Share-based compensation awards		$ 7		$ 17		(9)
Treasury stock acquired		(285)		(285)
Dividends, Common Stock		$ (174)					(174)
Ending balance (in shares) at Mar. 31, 2023		501,891,243	501,900,000
Ending balance at Mar. 31, 2023		$ 4,491	$ 5	$ (4,807)		$ 1,079	$ 9,045	$ (828)	$ (3)
Treasury stock, ending balance (in shares) at Mar. 31, 2023		39,395,900		39,400,000

[1] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Operating Activities
Net income before allocation to noncontrolling interests		$ 551	$ 594
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization expense	[1],[2]	120	114
Share-based compensation expense		9	16
Asset write-offs and asset impairments		1	1
Provision for losses on inventory		16	9
Deferred taxes		8	(45)
Employee benefit plan contribution from Pfizer Inc.		0	1
Other non-cash adjustments		(1)	4
Other changes in assets and liabilities, net of acquisitions and divestitures:
Accounts receivable		27	(102)
Inventories		(235)	(146)
Other assets		(24)	(1)
Accounts payable		22	(31)
Other liabilities		(63)	(222)
Other tax accounts, net		118	117
Net cash provided by operating activities		549	309
Investing Activities
Capital expenditures		(223)	(115)
Acquisitions		(7)	(4)
Purchase of investments		(1)	(5)
Proceeds on derivative instrument activity, net		13	6
Net proceeds from sale of assets		2	0
Net cash used in investing activities		(216)	(118)
Financing Activities
Increase in short-term borrowings, net		1	0
Principal payments on long-term debt		(1,350)	0
Share-based compensation-related proceeds, net of taxes paid on withholding shares		4	(30)
Purchases of treasury stock		(283)	(361)
Cash dividends paid		(174)	(154)
Net cash used in financing activities		(1,802)	(545)
Effect of exchange-rate changes on cash and cash equivalents		(3)	4
Net decrease in cash and cash equivalents		(1,472)	(350)
Cash and cash equivalents at beginning of period		3,581	3,485
Cash and cash equivalents at end of period		2,109	3,135
Cash paid during the period for:
Income taxes		20	26
Interest, net of capitalized interest		89	89
Amounts included in the measurement of lease liabilities		14	13
Non-cash transactions:
Capital expenditures		3	4
Excise tax accrued on net share repurchases, not paid		2	0
Lease obligations obtained in exchange for right-of-use assets		13	$ 19
Dividends declared, not paid		$ 174

[1] Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

[2] Defined as income before provision for taxes on income.

XML

Organization

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

1. Organization

Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. We organize and operate our business in two geographic regions: the United States (U.S.) and International.

We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, other pharmaceutical products, dermatology, anti-infectives, medicated feed additives and animal health diagnostics.

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three months ended February 28, 2023 and February 28, 2022.

Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2022 Annual Report on Form 10-K.

XML

Accounting Standards

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Accounting Standards

3. Accounting Standards

Recently Adopted Accounting Standards

XML

Revenue

3 Months Ended

Mar. 31, 2023

Revenue Recognition and Deferred Revenue [Abstract]

Revenue

4. Revenue

A. Revenue from Product Sales

We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers or e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top-selling product lines are distributed across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.

Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock within each of our major product categories.

Our major product categories are:

•parasiticides: products that prevent or eliminate external and internal parasites such as fleas, ticks and worms;

•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;

•other pharmaceutical products: pain and sedation, antiemetic, reproductive, and oncology products;

•dermatology products: products that relieve itch associated with allergic conditions and atopic dermatitis;

•anti-infectives: products that prevent, kill or slow the growth of bacteria, fungi or protozoa;

•animal health diagnostics: testing and analysis of blood, urine and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services and blood glucose monitors; and

•medicated feed additives: products added to animal feed that provide medicines to livestock.

Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals, as well as products and services in biodevices, genetic tests and precision animal health.

Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, deepening the human-animal bond, receiving increased medical treatment and benefiting from advances in animal health medicine, vaccines and diagnostics.

Our livestock products primarily help prevent or treat diseases and conditions to allow veterinarians and producers to care for their animals and to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive demand for improved nutrition, particularly through increased consumption of animal protein. Second, population growth leads to greater natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve and the global food chain faces increased scrutiny, there is more focus on food quality, safety and reliability of supply.

The following tables present our revenue disaggregated by geographic area, species and major product category:

Revenue by geographic area

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
United States	$	1,005	$	1,020
Australia	82		65
Brazil	84		77
Canada	50		49
Chile	39		41
China	102		103
France	34		32
Germany	45		43
Italy	26		30
Japan	39		59
Mexico	39		35
Spain	33		33
United Kingdom	68		64
Other developed markets	122		115
Other emerging markets	215		202
	1,983		1,968
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue by major species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
U.S.
Companion animal	$	721	$	774
Livestock	284		246
	1,005		1,020
International
Companion animal	504		489
Livestock	474		459
	978		948
Total
Companion animal	1,225		1,263
Livestock	758		705
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue by species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Companion Animal:
Dogs and Cats	$	1,153	$	1,199
Horses	72		64
	1,225		1,263
Livestock:
Cattle	399		364
Swine	142		154
Poultry	139		124
Fish	49		44
Sheep and other	29		19
	758		705
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue by major product category

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Parasiticides	$	432	$	459
Vaccines	429		405
Other pharmaceuticals	294		254
Dermatology	292		311
Anti-infectives	288		285
Animal health diagnostics	93		98
Medicated feed additives	87		98
Other non-pharmaceuticals	68		58
	1,983		1,968
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

B. Revenue from Contracts with Customers

Contract liabilities reflected within Other current liabilities as of December 31, 2022 and 2021, and subsequently recognized as revenue during the first three months of 2023 and 2022 were $1 million and $2 million, respectively. Contract liabilities as of March 31, 2023 and December 31, 2022 were $14 million.

Estimated future revenue expected to be generated from long-term contracts with unsatisfied performance obligations as of March 31, 2023 is not material.

XML

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

3 Months Ended

Mar. 31, 2023

Restructuring and Related Activities [Abstract]

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

6. Restructuring Charges and Other Costs Associated with Acquisitions, Cost-Reduction and Productivity
Initiatives

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. In connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as functions such as business technology, shared services and corporate operations.

The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Restructuring charges and certain acquisition-related costs:
Integration costs(a)	$	1	$	2
Restructuring charges(b):
Employee termination costs	20		—
Total Restructuring charges and certain acquisition-related costs	$	21	$	2

(a)    Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

(b)    The restructuring charges for the three months ended March 31, 2023 primarily consisted of employee termination costs related to organizational structure refinements.

(MILLIONS OF DOLLARS)	Accrual
Balance, December 31, 2022(a)	$	15
Provision	20
Utilization and other(b)	(3)
Balance, March 31, 2023(a)	$	32

(a)     At March 31, 2023 and December 31, 2022, included in Accrued expenses ($22 million and $5 million, respectively) and Other noncurrent liabilities ($10 million).

(b)     Includes adjustments for foreign currency translation.

XML

Other (Income)/Deductions - Net

3 Months Ended

Mar. 31, 2023

Other Income and Expenses [Abstract]

Other (Income)/Deductions - Net

7. Other (Income)/Deductions—Net

The components of Other (income)/deductions—net are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Royalty-related income(a)	$	(34)	$	(1)
Interest income	(33)		(2)
Foreign currency loss(b)	9		11
Other, net	5		(1)
Other (income)/deductions—net	$	(53)	$	7

(a)     For the three months ended March 31, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.

(b)     Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.

XML

Income Taxes

3 Months Ended

Mar. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

A. Taxes on Income

Our effective tax rate was 20.9% for the three months ended March 31, 2023, compared with 18.3% for the three months ended March 31, 2022. The higher effective tax rate for the three months ended March 31, 2023, was attributable to lower net discrete tax benefits for the three months ended March 31, 2023 and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income for the three months ended March 31, 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.

In 2022, the company implemented an initiative to maximize its cash position in the U.S. This initiative resulted in a tax benefit in the U.S. in connection with a prepayment from a related foreign entity in Belgium which qualifies as foreign-derived intangible income; however, this income tax benefit was deferred for 2022. A portion of this benefit was recognized during the three months ended March 31, 2023.

B. Deferred Taxes

As of March 31, 2023, the total net deferred income tax asset of $30 million is included in Noncurrent deferred tax assets ($161 million) and Noncurrent deferred tax liabilities ($131 million).

As of December 31, 2022, the total net deferred income tax asset of $31 million is included in Noncurrent deferred tax assets ($173 million) and Noncurrent deferred tax liabilities ($142 million).

C. Tax Contingencies

As of March 31, 2023, the net tax liabilities associated with uncertain tax positions of $196 million (exclusive of interest and penalties related to uncertain tax positions of $21 million) are included in Noncurrent deferred tax assets and Other noncurrent assets ($1 million) and Other taxes payable ($195 million).

As of December 31, 2022, the net tax liabilities associated with uncertain tax positions of $194 million (exclusive of interest and penalties related to uncertain tax positions of $19 million) are included in Noncurrent deferred tax assets and Other noncurrent assets ($2 million) and Other taxes payable ($192 million).

Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

XML

Financial Instruments

3 Months Ended

Mar. 31, 2023

Financial Instruments [Abstract]

Financial Instruments

9. Financial Instruments

A. Debt

Credit Facilities

In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. The credit facility replaced the company's existing revolving credit facility dated as of December 2016. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.

We were in compliance with all financial covenants as of March 31, 2023 and December 31, 2022. There were no amounts drawn under the credit facility as of March 31, 2023 or December 31, 2022.

We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of March 31, 2023, we had access to $51 million of lines of credit which expire at various times and are generally renewed annually. There were $3 million of borrowings outstanding related to these facilities as of March 31, 2023 and $2 million of borrowings outstanding related to these facilities as of December 31, 2022.

Commercial Paper Program

In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of March 31, 2023 and December 31, 2022, there was no commercial paper outstanding under this program.

Senior Notes and Other Long-Term Debt

On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.

Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

The components of our long-term debt are as follows:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
3.250% 2013 senior notes due 2023	$	—	$	1,350
4.500% 2015 senior notes due 2025	750		750
5.400% 2022 senior notes due 2025	600		600
3.000% 2017 senior notes due 2027	750		750
3.900% 2018 senior notes due 2028	500		500
2.000% 2020 senior notes due 2030	750		750
5.600% 2022 senior notes due 2032	750		750
4.700% 2013 senior notes due 2043	1,150		1,150
3.950% 2017 senior notes due 2047	500		500
4.450% 2018 senior notes due 2048	400		400
3.000% 2020 senior notes due 2050	500		500
	6,650		8,000
Unamortized debt discount / debt issuance costs	(65)		(66)
Less current portion of long-term debt	—		1,350
Cumulative fair value adjustment for interest rate swap contracts	(26)		(32)
Long-term debt, net of discount and issuance costs	$	6,559	$	6,552

The fair value of our long-term debt was $6,273 million and $6,108 million as of March 31, 2023 and December 31, 2022, respectively, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from, or corroborated by, observable market data and Zoetis’ credit rating (Level 2 inputs).

The principal amount of long-term debt outstanding, as of March 31, 2023, matures in the following years:

											After
(MILLIONS OF DOLLARS)	2023		2024		2025		2026		2027		2027		Total
Maturities	$	—	$	—	$	1,350	$	—	$	750	$	4,550	$	6,650

Interest Expense

Interest expense, net of capitalized interest, was $63 million and $53 million for the three months ended March 31, 2023 and 2022, respectively. Capitalized interest expense was $6 million and $5 million for the three months ended March 31, 2023 and 2022, respectively.

B. Derivative Financial Instruments

Foreign Exchange Risk

A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.

All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the Condensed Consolidated Balance Sheets. The derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Chinese yuan, euro, Japanese yen and Norwegian krone. Changes in fair value are reported in earnings or in Accumulated other comprehensive income/(loss), depending on the nature and purpose of the financial instrument, as follows:

•For foreign currency forward-exchange contracts not designated as hedging instruments, we recognize the gains and losses that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The vast majority of the foreign currency forward-exchange contracts mature within 60 days and all mature within three years.

•For foreign exchange derivative instruments that are designated as hedging instruments against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within Accumulated other comprehensive income/(loss) and reclassified into earnings when the foreign investment is sold or substantially liquidated. These instruments include cross-currency interest rate swaps and foreign currency forward-exchange contracts. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (Interest expense, net of capitalized interest). The cash flows from these contracts are reflected within the investing section of our Condensed Consolidated Statements of Cash Flows. These contracts have varying maturities of up to three years.

Interest Rate Risk

The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing.

•In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in Accumulated other comprehensive loss and are recognized in earnings over the life of the future fixed rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.

•During the period from 2019 to 2022, we entered into forward-starting interest rate swaps with an aggregate notional value of $650 million. We designated these swaps as cash flow hedges against interest rate exposure related principally to the issuance of fixed-rate debt to refinance our 3.250% 2013 senior notes due 2023. Upon issuance of our 2022 senior notes, we terminated these contracts and received $114 million in cash from the counterparties for settlement, included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows. The settlement amount, which represented the fair value of the contracts at the time of termination, was recorded in Accumulated other comprehensive loss, and will be amortized into income (offset to Interest expense, net of capitalized interest) over the life of the 5.600% 2022 senior notes due 2032.

•As of March 31, 2023, we had outstanding a forward-starting interest rate swap, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500% 2015 senior notes due 2025.

•We may use fixed-to-floating interest rate swaps that are designated as fair value hedges to hedge against changes in the fair value of certain fixed-rate debt attributable to changes in the benchmark the Secured Overnight Financing Rate (SOFR). These derivative instruments effectively convert a portion of the company’s long-term debt from fixed-rate to floating-rate debt based on the daily SOFR rate plus a spread. Gains or losses on the fixed-to-floating interest rate swaps due to changes in SOFR are recorded in Interest expense, net of capitalized interest. Changes in the fair value of the fixed-to-floating interest rate swaps are offset by changes in the fair value of the underlying fixed-rate debt. As of March 31, 2023, we had outstanding fixed-to-floating interest rate swaps that correspond to a portion of the 3.900% 2018 senior notes due 2028 and the 2.000% senior notes due 2030. The amounts recorded during the three months ended March 31, 2023 for changes in the fair value of these hedges are not material to our condensed consolidated financial statements.

During the first quarter of 2023, we executed amendments to certain of our interest rate swap contracts, which changed the floating rate index from LIBOR to SOFR. These amendments did not have a material impact on our condensed consolidated financial statements.

Outstanding Positions

The aggregate notional amount of derivative instruments are as follows:

	Notional
	March 31,		December 31,
(MILLIONS)	2023		2022
Derivatives not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	$	1,716	$	1,753
Derivatives Designated as Hedging Instruments
Foreign exchange derivative instruments (in foreign currency):
Euro	650		650
Danish krone	600		600
Swiss franc	25		25
Forward-starting interest rate swaps	$	50	$	50
Fixed-to-floating interest rate swap contracts	$	250	$	250

Fair Value of Derivative Instruments

The classification and fair values of derivative instruments are as follows:

		Fair Value of Derivatives
		March 31,		December 31,
(MILLIONS OF DOLLARS)	Balance Sheet Location	2023		2022
Derivatives Not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	Other current assets	$	16	$	22
Foreign currency forward-exchange contracts	Other current liabilities	(15)		(21)
Total derivatives not designated as hedging instruments		$	1	$	1
Derivatives Designated as Hedging Instruments:
Forward-starting interest rate swap contracts	Other noncurrent assets	$	9	$	10
Foreign exchange derivative instruments	Other current assets	11		21
Foreign exchange derivative instruments	Other noncurrent assets	17		19
Foreign exchange derivative instruments	Other current liabilities	(14)		(9)
Foreign exchange derivative instruments	Other noncurrent liabilities	(6)		(4)
Fixed-to-floating interest rate swap contracts	Other noncurrent liabilities	(26)		(32)
Total derivatives designated as hedging instruments		(9)		5
Total derivatives		$	(8)	$	6

The company’s derivative transactions are subject to master netting agreements that mitigate credit risk by permitting net settlement of transactions with the same counterparty. The company also has collateral security agreements with certain of its counterparties. Under these collateral security agreements either party is required to post cash collateral when the net fair value of derivative instruments covered by the collateral agreement exceeds contractually established thresholds. At March 31, 2023, there was $6 million of collateral received and $21 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively. At December 31, 2022, there was $8 million of collateral received and $21 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively.

We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.

The amounts of net losses on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Foreign currency forward-exchange contracts	$	(16)	$	(6)

These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.

The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Forward-starting interest rate swap contracts	$	(1)	$	26
Foreign exchange derivative instruments	$	(6)	$	12

Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Foreign exchange derivative instruments	$	5	$	3

The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from Accumulated other comprehensive loss into earnings over the next 12 months is not material.

XML

Inventories

3 Months Ended

Mar. 31, 2023

Inventory Disclosure [Abstract]

Inventories

10. Inventories

The components of inventory are as follows:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
Finished goods	$	1,065	$	1,090
Work-in-process	999		825
Raw materials and supplies	499		430
Inventories	$	2,563	$	2,345

XML

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

11. Goodwill and Other Intangible Assets

A. Goodwill

The components of, and changes in, the carrying amount of goodwill are as follows:

(MILLIONS OF DOLLARS)	U.S.		International		Total
Balance, December 31, 2022	$	1,485	$	1,261	$	2,746
Adjustments	—		(1)		(1)
Other(a)	—		(7)		(7)
Balance, March 31, 2023	$	1,485	$	1,253	$	2,738

(a) Includes adjustments for foreign currency translation.

The gross goodwill balance was $3,274 million and $3,282 million as of March 31, 2023 and December 31, 2022, respectively. Accumulated goodwill impairment losses (generated entirely in fiscal 2002) were $536 million as of March 31, 2023 and December 31, 2022.

B. Other Intangible Assets

The components of identifiable intangible assets are as follows:

	As of March 31, 2023						As of December 31, 2022
					Identifiable						Identifiable
	Gross				Intangible Assets		Gross				Intangible Assets
	Carrying		Accumulated		Less Accumulated		Carrying		Accumulated		Less Accumulated
(MILLIONS OF DOLLARS)	Amount		Amortization		Amortization		Amount		Amortization		Amortization
Finite-lived intangible assets:
Developed technology rights	$	1,900	$	(1,006)	$	894	$	1,918	$	(975)	$	943
Brands and tradenames	390		(239)		151		395		(237)		158
Other	332		(238)		94		337		(233)		104
Total finite-lived intangible assets	2,622		(1,483)		1,139		2,650		(1,445)		1,205
Indefinite-lived intangible assets:
Brands and tradenames	91		—		91		91		—		91
In-process research and development	77		—		77		77		—		77
Product rights	7		—		7		7		—		7
Total indefinite-lived intangible assets	175		—		175		175		—		175
Identifiable intangible assets	$	2,797	$	(1,483)	$	1,314	$	2,825	$	(1,445)	$	1,380

C. Amortization

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $47 million and $52 million for the three months ended March 31, 2023 and 2022, respectively.

XML

Share-Based Payments

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Share-Based Payments

12. Share-based Payments

The Zoetis 2013 Equity and Incentive Plan (Equity Plan) provides long-term incentives to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards.

The components of share-based compensation expense are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Stock options / stock appreciation rights	$	1	$	2
RSUs / DSUs	7		9
PSUs	1		5
Share-based compensation expense—total(a)	$	9	$	16

(a) For the three months ended March 31, 2023 and 2022, we capitalized less than $1 million of share-based compensation expense to inventory.

During the three months ended March 31, 2023, the company granted 268,008 stock options with a weighted-average exercise price of $162.07 per stock option and a weighted-average fair value of $43.56 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 3.84%; expected dividend yield of 0.92%; expected stock price volatility of 28.63%; and expected term of 4.2 years. In general, stock options granted prior to 2023 vest after three years of continuous service, while stock options granted in 2023 are subject to graded vesting over three years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

During the three months ended March 31, 2023, the company granted 262,508 RSUs, with a weighted-average grant date fair value of $162.08 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs granted prior to 2023 vest after three years of continuous service from the grant date while RSUs granted in 2023 are subject to graded vesting over three years. The values generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

During the three months ended March 31, 2023, the company granted 99,626 PSUs with a weighted-average grant date fair value of $238.24 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies comprising the S&P 500 stock market index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&P 500 companies, which were 31.8% and 40.9%, respectively. Depending on the company’s Relative TSR performance at the end of the performance period, the recipient may earn from 0% to 200% of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

Stockholders' Equity

13. Stockholders' Equity

Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.

In December 2021, our Board of Directors authorized a $3.5 billion share repurchase program. As of March 31, 2023, there was $2.3 billion remaining under this authorization. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs.

Accumulated other comprehensive loss

Changes, net of tax, in accumulated other comprehensive loss, were as follows:

			Currency Translation Adjustments
					Other Currency		Benefit Plans		Accumulated Other
	Cash Flow		Net Investment		Translation		Actuarial		Comprehensive
(MILLIONS OF DOLLARS)	Hedges		Hedges		Adjustments		(Losses)/Gains		Loss
Balance, December 31, 2022	$	90	$	41	$	(944)	$	(4)	$	(817)
Other comprehensive (loss)/income, net of tax	(2)		(6)		(7)		4		(11)
Balance, March 31, 2023	$	88	$	35	$	(951)	$	—	$	(828)
Balance, December 31, 2021	$	4	$	5	$	(756)	$	(17)	$	(764)
Other comprehensive income, net of tax	26		12		21		1		60
Balance, March 31, 2022	$	30	$	17	$	(735)	$	(16)	$	(704)

XML

Earnings per Share

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Earnings per Share

14. Earnings per Share

The following table presents the calculation of basic and diluted earnings per share:

	Three Months Ended
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	March 31,
	2023		2022
Numerator
Net income before allocation to noncontrolling interests	$	551	$	594
Less: Net loss attributable to noncontrolling interests	(1)		(1)
Net income attributable to Zoetis Inc.	$	552	$	595
Denominator
Weighted-average common shares outstanding	463.5		472.2
Common stock equivalents: stock options, RSUs, PSUs and DSUs	1.1		1.9
Weighted-average common and potential dilutive shares outstanding	464.6		474.1
Earnings per share attributable to Zoetis Inc. stockholders—basic	$	1.19	$	1.26
Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	1.19	$	1.26

The number of stock options outstanding under the company's Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were not material for the three months ended March 31, 2023 and 2022.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. Commitments and Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 8. Income Taxes.

A. Legal Proceedings

Our non-tax contingencies include, among others, the following:

•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.

•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.

•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.

•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.

The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.

Ulianopolis, Brazil

In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.

The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.

At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area.

On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. The defendants presented the technical proposal to the Prosecutor on October 21, 2019. On March 3, 2020, the Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor. On July 15, 2020, the Prosecutor recommended certain amendments to the proposal for the Phase II testing. On September 28, 2020, the parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing. Due to the ongoing issues presented by the coronavirus (COVID-19) pandemic, the parties have been unable to secure a start date for the Phase II testing and have no timeline at this point when testing will begin.

Belgium Excess Profit Tax Regime

On February 14, 2019, the General Court of the European Union (General Court) annulled the January 11, 2016 decision of the European Commission (EC) that selective tax advantages granted by Belgium under its "excess profit" tax scheme constitute illegal state aid. As a result of the 2016 decision, the company recorded a net tax charge of approximately $35 million in the first half of 2016. On May 8, 2019, the EC filed an appeal to the decision of the General Court. On September 16, 2019, the EC opened separate in-depth investigations to assess whether Belgium excess profit rulings granted to 39 multinational companies, including Zoetis, constituted state aid for those companies. On September 16, 2021, the European Court of Justice upheld the EC’s decision that the Belgium excess profit ruling system is considered an aid scheme and referred the case back to the General Court to rule on open questions. On May 24, 2022, the General Court resumed all proceedings involved with the Excess Profit Rulings cases, including Zoetis. On June 23, 2022, as requested by the General Court, the company provided observations in relations to (i) the impact of the Court of Justice’s decision that the Belgium excess profit ruling system is considered an aid scheme and (ii) the impact of recent case laws by the General Court with regards to the existence of a selective advantage. On December 16, 2022, the company submitted observations on the conclusions drawn from the November 8, 2022 Fiat Chrysler Finance Europe and Ireland v Commission judgement, as requested by the General Court. A hearing by the General Court took place on February 15, 2023 and we are now awaiting a decision on our plea. The company has not reflected any potential benefits in its condensed consolidated financial statements as of March 31, 2023 as a result of the 2019 annulment. We will continue to monitor the developments of the appeal and its ultimate resolution.

B. Guarantees and Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 31, 2023, recorded amounts for the estimated fair value of these indemnifications were not material.

XML

Segment Information

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Segment Information

16. Segment Information

Operating Segments

We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, other pharmaceutical products, dermatology, anti-infectives, medicated feed additives and animal health diagnostics, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

•    Other business activities, includes our Client Supply Services (CSS) contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.

•    Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.

•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition-related activities, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.

•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) procurement costs.

Segment Assets

We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

Selected Statement of Income Information    

	Earnings						Depreciation and Amortization(a)
	Three Months Ended						Three Months Ended
	March 31,						March 31,
(MILLIONS OF DOLLARS)	2023			2022			2023		2022
U.S.
Revenue	$	1,005		$	1,020
Cost of sales	203			185
Gross profit	802			835
Gross margin	79.8		%	81.9		%
Operating expenses	188			165
Other (income)/deductions-net	—			—
U.S. Earnings	614			670			$	19	$	13
International
Revenue(b)	978			948
Cost of sales	291			265
Gross profit	687			683
Gross margin	70.2		%	72.0		%
Operating expenses	151			145
Other (income)/deductions-net	1			—
International Earnings	535			538			21		18
Total operating segments	1,149			1,208			40		31
Other business activities	(114)			(98)			8		7
Reconciling Items:
Corporate	(208)			(259)			32		35
Purchase accounting adjustments	(42)			(40)			39		40
Acquisition-related costs	(1)			(2)			—		—
Certain significant items(c)	(22)			—			—		—
Other unallocated	(65)			(82)			1		1
Total Earnings(d)	$	697		$	727		$	120	$	114

(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

(b)    Revenue denominated in euros was $204 million and $203 million for the three months ended March 31, 2023 and 2022, respectively.

(c)    For the three months ended March 31, 2023, primarily consisted of employee termination costs related to organizational structure refinements.

For the three months ended March 31, 2022, primarily consisted of product transfer costs offset by other items.

(d)    Defined as income before provision for taxes on income.

XML

Accounting Standards (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three months ended February 28, 2023 and February 28, 2022.

Recently Adopted Accounting Standards and Recently Issued Accounting Standards

Recently Adopted Accounting Standards

Tax Contingencies

Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

Legal Proceedings

A. Legal Proceedings

Our non-tax contingencies include, among others, the following:

•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.

•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.

•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.

•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.

The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.

Guarantees and Indemnifications

B. Guarantees and IndemnificationsIn the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 31, 2023, recorded amounts for the estimated fair value of these indemnifications were not material.

Segment Information

Operating Segments

We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, other pharmaceutical products, dermatology, anti-infectives, medicated feed additives and animal health diagnostics, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

•    Other business activities, includes our Client Supply Services (CSS) contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.

•    Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.

•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition-related activities, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.

•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) procurement costs.

Segment Assets

We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

XML

Revenue Revenue Recognition and Deferred Revenue (Tables)

3 Months Ended

Mar. 31, 2023

Revenue Recognition and Deferred Revenue [Abstract]

Revenue from External Customers by Geographic Areas

The following tables present our revenue disaggregated by geographic area, species and major product category:

Revenue by geographic area

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
United States	$	1,005	$	1,020
Australia	82		65
Brazil	84		77
Canada	50		49
Chile	39		41
China	102		103
France	34		32
Germany	45		43
Italy	26		30
Japan	39		59
Mexico	39		35
Spain	33		33
United Kingdom	68		64
Other developed markets	122		115
Other emerging markets	215		202
	1,983		1,968
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue from External Customers by Major Species

Revenue by major species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
U.S.
Companion animal	$	721	$	774
Livestock	284		246
	1,005		1,020
International
Companion animal	504		489
Livestock	474		459
	978		948
Total
Companion animal	1,225		1,263
Livestock	758		705
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Revenue from External Customers by Species

Revenue by species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Companion Animal:
Dogs and Cats	$	1,153	$	1,199
Horses	72		64
	1,225		1,263
Livestock:
Cattle	399		364
Swine	142		154
Poultry	139		124
Fish	49		44
Sheep and other	29		19
	758		705
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

Schedule of Significant Product Revenues

Revenue by major product category

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Parasiticides	$	432	$	459
Vaccines	429		405
Other pharmaceuticals	294		254
Dermatology	292		311
Anti-infectives	288		285
Animal health diagnostics	93		98
Medicated feed additives	87		98
Other non-pharmaceuticals	68		58
	1,983		1,968
Contract manufacturing & human health	17		18
Total Revenue	$	2,000	$	1,986

XML

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)

3 Months Ended

Mar. 31, 2023

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Restructuring charges and certain acquisition-related costs:
Integration costs(a)	$	1	$	2
Restructuring charges(b):
Employee termination costs	20		—
Total Restructuring charges and certain acquisition-related costs	$	21	$	2

(a)    Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

(b)    The restructuring charges for the three months ended March 31, 2023 primarily consisted of employee termination costs related to organizational structure refinements.

(MILLIONS OF DOLLARS)	Accrual
Balance, December 31, 2022(a)	$	15
Provision	20
Utilization and other(b)	(3)
Balance, March 31, 2023(a)	$	32

(a)     At March 31, 2023 and December 31, 2022, included in Accrued expenses ($22 million and $5 million, respectively) and Other noncurrent liabilities ($10 million).

(b)     Includes adjustments for foreign currency translation.

XML

Other (Income)/Deductions - Net (Tables)

3 Months Ended

Mar. 31, 2023

Other Income and Expenses [Abstract]

Components of Other (Income)/Deductions—Net

The components of Other (income)/deductions—net are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Royalty-related income(a)	$	(34)	$	(1)
Interest income	(33)		(2)
Foreign currency loss(b)	9		11
Other, net	5		(1)
Other (income)/deductions—net	$	(53)	$	7

(a)     For the three months ended March 31, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.

(b)     Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.

XML

Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2023

Financial Instruments [Abstract]

Schedule of Long-term Debt Instruments

The components of our long-term debt are as follows:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
3.250% 2013 senior notes due 2023	$	—	$	1,350
4.500% 2015 senior notes due 2025	750		750
5.400% 2022 senior notes due 2025	600		600
3.000% 2017 senior notes due 2027	750		750
3.900% 2018 senior notes due 2028	500		500
2.000% 2020 senior notes due 2030	750		750
5.600% 2022 senior notes due 2032	750		750
4.700% 2013 senior notes due 2043	1,150		1,150
3.950% 2017 senior notes due 2047	500		500
4.450% 2018 senior notes due 2048	400		400
3.000% 2020 senior notes due 2050	500		500
	6,650		8,000
Unamortized debt discount / debt issuance costs	(65)		(66)
Less current portion of long-term debt	—		1,350
Cumulative fair value adjustment for interest rate swap contracts	(26)		(32)
Long-term debt, net of discount and issuance costs	$	6,559	$	6,552

Schedule of Maturities of Long-term Debt

The principal amount of long-term debt outstanding, as of March 31, 2023, matures in the following years:

											After
(MILLIONS OF DOLLARS)	2023		2024		2025		2026		2027		2027		Total
Maturities	$	—	$	—	$	1,350	$	—	$	750	$	4,550	$	6,650

Schedule of Derivative Instruments

The aggregate notional amount of derivative instruments are as follows:

	Notional
	March 31,		December 31,
(MILLIONS)	2023		2022
Derivatives not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	$	1,716	$	1,753
Derivatives Designated as Hedging Instruments
Foreign exchange derivative instruments (in foreign currency):
Euro	650		650
Danish krone	600		600
Swiss franc	25		25
Forward-starting interest rate swaps	$	50	$	50
Fixed-to-floating interest rate swap contracts	$	250	$	250

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The classification and fair values of derivative instruments are as follows:

		Fair Value of Derivatives
		March 31,		December 31,
(MILLIONS OF DOLLARS)	Balance Sheet Location	2023		2022
Derivatives Not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	Other current assets	$	16	$	22
Foreign currency forward-exchange contracts	Other current liabilities	(15)		(21)
Total derivatives not designated as hedging instruments		$	1	$	1
Derivatives Designated as Hedging Instruments:
Forward-starting interest rate swap contracts	Other noncurrent assets	$	9	$	10
Foreign exchange derivative instruments	Other current assets	11		21
Foreign exchange derivative instruments	Other noncurrent assets	17		19
Foreign exchange derivative instruments	Other current liabilities	(14)		(9)
Foreign exchange derivative instruments	Other noncurrent liabilities	(6)		(4)
Fixed-to-floating interest rate swap contracts	Other noncurrent liabilities	(26)		(32)
Total derivatives designated as hedging instruments		(9)		5
Total derivatives		$	(8)	$	6

Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location

The amounts of net losses on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Foreign currency forward-exchange contracts	$	(16)	$	(6)

Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)

The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Forward-starting interest rate swap contracts	$	(1)	$	26
Foreign exchange derivative instruments	$	(6)	$	12

Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location

Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Foreign exchange derivative instruments	$	5	$	3

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2023

Inventory Disclosure [Abstract]

Components of Inventory

The components of inventory are as follows:

	March 31,		December 31,
(MILLIONS OF DOLLARS)	2023		2022
Finished goods	$	1,065	$	1,090
Work-in-process	999		825
Raw materials and supplies	499		430
Inventories	$	2,563	$	2,345

XML

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in the Carrying Amount of Goodwill

The components of, and changes in, the carrying amount of goodwill are as follows:

(MILLIONS OF DOLLARS)	U.S.		International		Total
Balance, December 31, 2022	$	1,485	$	1,261	$	2,746
Adjustments	—		(1)		(1)
Other(a)	—		(7)		(7)
Balance, March 31, 2023	$	1,485	$	1,253	$	2,738

(a) Includes adjustments for foreign currency translation.

Components of Identifiable Intangible Assets

The components of identifiable intangible assets are as follows:

	As of March 31, 2023						As of December 31, 2022
					Identifiable						Identifiable
	Gross				Intangible Assets		Gross				Intangible Assets
	Carrying		Accumulated		Less Accumulated		Carrying		Accumulated		Less Accumulated
(MILLIONS OF DOLLARS)	Amount		Amortization		Amortization		Amount		Amortization		Amortization
Finite-lived intangible assets:
Developed technology rights	$	1,900	$	(1,006)	$	894	$	1,918	$	(975)	$	943
Brands and tradenames	390		(239)		151		395		(237)		158
Other	332		(238)		94		337		(233)		104
Total finite-lived intangible assets	2,622		(1,483)		1,139		2,650		(1,445)		1,205
Indefinite-lived intangible assets:
Brands and tradenames	91		—		91		91		—		91
In-process research and development	77		—		77		77		—		77
Product rights	7		—		7		7		—		7
Total indefinite-lived intangible assets	175		—		175		175		—		175
Identifiable intangible assets	$	2,797	$	(1,483)	$	1,314	$	2,825	$	(1,445)	$	1,380

XML

Share-Based Payments (Tables)

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Components of Share-based Compensation Expense

The components of share-based compensation expense are as follows:

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2023		2022
Stock options / stock appreciation rights	$	1	$	2
RSUs / DSUs	7		9
PSUs	1		5
Share-based compensation expense—total(a)	$	9	$	16

(a) For the three months ended March 31, 2023 and 2022, we capitalized less than $1 million of share-based compensation expense to inventory.

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

Changes, Net of Tax, in Accumulated Other Comprehensive Loss

Changes, net of tax, in accumulated other comprehensive loss, were as follows:

			Currency Translation Adjustments
					Other Currency		Benefit Plans		Accumulated Other
	Cash Flow		Net Investment		Translation		Actuarial		Comprehensive
(MILLIONS OF DOLLARS)	Hedges		Hedges		Adjustments		(Losses)/Gains		Loss
Balance, December 31, 2022	$	90	$	41	$	(944)	$	(4)	$	(817)
Other comprehensive (loss)/income, net of tax	(2)		(6)		(7)		4		(11)
Balance, March 31, 2023	$	88	$	35	$	(951)	$	—	$	(828)
Balance, December 31, 2021	$	4	$	5	$	(756)	$	(17)	$	(764)
Other comprehensive income, net of tax	26		12		21		1		60
Balance, March 31, 2022	$	30	$	17	$	(735)	$	(16)	$	(704)

XML

Earnings per Share (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Basic and Diluted Earnings Per Share

The following table presents the calculation of basic and diluted earnings per share:

	Three Months Ended
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	March 31,
	2023		2022
Numerator
Net income before allocation to noncontrolling interests	$	551	$	594
Less: Net loss attributable to noncontrolling interests	(1)		(1)
Net income attributable to Zoetis Inc.	$	552	$	595
Denominator
Weighted-average common shares outstanding	463.5		472.2
Common stock equivalents: stock options, RSUs, PSUs and DSUs	1.1		1.9
Weighted-average common and potential dilutive shares outstanding	464.6		474.1
Earnings per share attributable to Zoetis Inc. stockholders—basic	$	1.19	$	1.26
Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	1.19	$	1.26

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of Selected Income Statement Information by Segment

	Earnings						Depreciation and Amortization(a)
	Three Months Ended						Three Months Ended
	March 31,						March 31,
(MILLIONS OF DOLLARS)	2023			2022			2023		2022
U.S.
Revenue	$	1,005		$	1,020
Cost of sales	203			185
Gross profit	802			835
Gross margin	79.8		%	81.9		%
Operating expenses	188			165
Other (income)/deductions-net	—			—
U.S. Earnings	614			670			$	19	$	13
International
Revenue(b)	978			948
Cost of sales	291			265
Gross profit	687			683
Gross margin	70.2		%	72.0		%
Operating expenses	151			145
Other (income)/deductions-net	1			—
International Earnings	535			538			21		18
Total operating segments	1,149			1,208			40		31
Other business activities	(114)			(98)			8		7
Reconciling Items:
Corporate	(208)			(259)			32		35
Purchase accounting adjustments	(42)			(40)			39		40
Acquisition-related costs	(1)			(2)			—		—
Certain significant items(c)	(22)			—			—		—
Other unallocated	(65)			(82)			1		1
Total Earnings(d)	$	697		$	727		$	120	$	114

(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

(b)    Revenue denominated in euros was $204 million and $203 million for the three months ended March 31, 2023 and 2022, respectively.

(c)    For the three months ended March 31, 2023, primarily consisted of employee termination costs related to organizational structure refinements.

For the three months ended March 31, 2022, primarily consisted of product transfer costs offset by other items.

(d)    Defined as income before provision for taxes on income.

XML

Organization (Details)	Mar. 31, 2023 specie productCategory country geographicRegion
Product Information [Line Items]
Number of regional segments | geographicRegion	2
Number of countries in which entity markets products	45
Number of core animal species | specie	8
Number of major product categories | productCategory	7
Product
Product Information [Line Items]
Number of countries in which entity markets products	100

XML

Revenue - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) product_category	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Revenue Recognition and Deferred Revenue [Abstract]
Number of major product lines | product_category	300
Contract liabilities, revenue recognized	$ 1	$ 2
Contract liabilities	$ 14		$ 14

XML

Revenue - Revenue by Geographic Area (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from External Customer [Line Items]
Revenue	$ 2,000	$ 1,986
United States
Revenue from External Customer [Line Items]
Revenue	1,005	1,020
Australia
Revenue from External Customer [Line Items]
Revenue	82	65
Brazil
Revenue from External Customer [Line Items]
Revenue	84	77
Canada
Revenue from External Customer [Line Items]
Revenue	50	49
Chile
Revenue from External Customer [Line Items]
Revenue	39	41
China
Revenue from External Customer [Line Items]
Revenue	102	103
France
Revenue from External Customer [Line Items]
Revenue	34	32
Germany
Revenue from External Customer [Line Items]
Revenue	45	43
Italy
Revenue from External Customer [Line Items]
Revenue	26	30
Japan
Revenue from External Customer [Line Items]
Revenue	39	59
Mexico
Revenue from External Customer [Line Items]
Revenue	39	35
Spain
Revenue from External Customer [Line Items]
Revenue	33	33
United Kingdom
Revenue from External Customer [Line Items]
Revenue	68	64
Other developed markets
Revenue from External Customer [Line Items]
Revenue	122	115
Other emerging markets
Revenue from External Customer [Line Items]
Revenue	215	202
Total geographical area
Revenue from External Customer [Line Items]
Revenue	1,983	1,968
Contract manufacturing & human health
Revenue from External Customer [Line Items]
Revenue	$ 17	$ 18

XML

Revenue - Revenue by Major Species (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Revenue from External Customer [Line Items]
Revenue		$ 2,000	$ 1,986
Contract manufacturing & human health
Revenue from External Customer [Line Items]
Revenue		17	18
Companion animal
Revenue from External Customer [Line Items]
Revenue		1,225	1,263
Companion animal | U.S.
Revenue from External Customer [Line Items]
Revenue		721	774
Companion animal | International
Revenue from External Customer [Line Items]
Revenue		504	489
Livestock
Revenue from External Customer [Line Items]
Revenue		758	705
Livestock | U.S.
Revenue from External Customer [Line Items]
Revenue		284	246
Livestock | International
Revenue from External Customer [Line Items]
Revenue		474	459
Operating Segments | U.S.
Revenue from External Customer [Line Items]
Revenue		1,005	1,020
Operating Segments | International
Revenue from External Customer [Line Items]
Revenue	[1]	$ 978	$ 948

[1] Revenue denominated in euros was $204 million and $203 million for the three months ended March 31, 2023 and 2022, respectively.

XML

Revenue - Revenue by Species (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from External Customer [Line Items]
Revenue	$ 2,000	$ 1,986
Contract manufacturing & human health
Revenue from External Customer [Line Items]
Revenue	17	18
Dogs and Cats
Revenue from External Customer [Line Items]
Revenue	1,153	1,199
Horses
Revenue from External Customer [Line Items]
Revenue	72	64
Cattle
Revenue from External Customer [Line Items]
Revenue	399	364
Swine
Revenue from External Customer [Line Items]
Revenue	142	154
Poultry
Revenue from External Customer [Line Items]
Revenue	139	124
Fish
Revenue from External Customer [Line Items]
Revenue	49	44
Sheep and other
Revenue from External Customer [Line Items]
Revenue	29	19
Livestock
Revenue from External Customer [Line Items]
Revenue	758	705
Companion animal
Revenue from External Customer [Line Items]
Revenue	1,225	1,263
Other pharmaceuticals
Revenue from External Customer [Line Items]
Revenue	$ 294	$ 254

XML

Revenue - Revenue by Product (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from External Customer [Line Items]
Revenue	$ 2,000	$ 1,986
Contract manufacturing & human health
Revenue from External Customer [Line Items]
Revenue	17	18
Vaccines
Revenue from External Customer [Line Items]
Revenue	429	405
Parasiticides
Revenue from External Customer [Line Items]
Revenue	432	459
Anti-infectives
Revenue from External Customer [Line Items]
Revenue	288	285
Dermatology
Revenue from External Customer [Line Items]
Revenue	292	311
Other pharmaceuticals
Revenue from External Customer [Line Items]
Revenue	294	254
Medicated feed additives
Revenue from External Customer [Line Items]
Revenue	87	98
Animal health diagnostics
Revenue from External Customer [Line Items]
Revenue	93	98
Other non-pharmaceuticals
Revenue from External Customer [Line Items]
Revenue	68	58
Total products and services
Revenue from External Customer [Line Items]
Revenue	$ 1,983	$ 1,968

XML

Acquisitions and Divestitures (Details) - Jurox - USD ($) $ in Millions		3 Months Ended
	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Business Combinations [Abstract]
Business Acquisition, Percentage of Voting Interests Acquired			100.00%
Asset Acquisition [Line Items]
Cash and cash equivalents	$ 20
Accounts receivable	8
Inventories	21
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	1
Property, plant and equipment	25
Identifiable intangible assets	135
Other noncurrent assets	1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	12
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	197
Goodwill, Acquired During Period	43
Payments to Acquire Businesses, Gross	240
Business Acquisition, Percentage of Voting Interests Acquired			100.00%
Business Combination, Consideration Transferred, Before Adjustments	$ 226
Business Combination, Consideration Transferred, Outstanding		$ 5

XML

Acquisitions and Divestitures - Consideration Transferred (Details) - Jurox - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 240
Business Combination, Consideration Transferred	240
Business Acquisition, Percentage of Voting Interests Acquired			100.00%
Business Combination, Consideration Transferred, Before Adjustments	$ 226
Acquisition of a noncontrolling interest, net of cash acquired			$ 215
Business Combination, Consideration Transferred, Outstanding		$ 5

XML

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022		Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Asset write-offs and asset impairments		$ 1	$ 1
Total Restructuring charges and certain acquisition-related costs		21	2
Restructuring Reserve [Roll Forward]
Restructuring accrual balance	[1],[2]	15
Restructuring charges (reversals)		20
Utilization and other	[1],[3]	(3)
Restructuring accrual balance	[1],[2]	32
Other current liabilities
Restructuring Reserve [Roll Forward]
Accrued expenses		22			$ 5
Other noncurrent liabilities
Restructuring Reserve [Roll Forward]
Other noncurrent liabilities		10			$ 10
Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Severance Costs		20	0
Direct Cost
Restructuring Cost and Reserve [Line Items]
Integration costs		$ 1	$ 2	[4]

[1] 1 

[2] At March 31, 2023 and December 31, 2022, included in Accrued expenses ($22 million and $5 million, respectively) and Other noncurrent liabilities ($10 million).

[3] Includes adjustments for foreign currency translation.

[4] Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

XML

Other (Income)/Deductions - Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty-related income(a)		$ (34)	$ (1)
Interest income		(33)	(2)
Foreign currency loss	[1]	9	11
Other, net		5	(1)
Other (income)/deductions—net		$ (53)	$ 7

[1] Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.

XML

Income Taxes - Taxes on Income (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Effective tax rate for income from continuing operations	20.90%	18.30%

XML

Income Taxes - Deferred Taxes (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Noncurrent deferred tax liabilities	$ 30	$ 31
Noncurrent deferred tax assets	161	173
Noncurrent deferred tax liabilities	$ 131	$ 142

XML

Income Taxes - Tax Contingencies (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Liabilities associated with uncertain tax positions	$ 196	$ 194
Unrecognized tax benefits, income tax penalties and interest accrued	21	19
Noncurrent Deferred Tax Assets
Income Tax Contingency [Line Items]
Liabilities associated with uncertain tax positions	1	2
Other Taxes Payable
Income Tax Contingency [Line Items]
Liabilities associated with uncertain tax positions	$ 195	$ 192

XML

Financial Instruments - Credit Facilities (Details)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 51,000,000
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments:
Line of Credit Facility [Line Items]
Collateral posted	$ 21,000,000	$ 21,000,000
Operational Efficiency
Line of Credit Facility [Line Items]
Maximum total leverage ratio	3.50
Maximum total leverage ratio, next 12 months	4.00
Revolving Credit Facility
Line of Credit Facility [Line Items]
Revolving credit facility, current borrowing capacity	$ 1,000,000,000
Line of credit facility, maximum borrowing capacity	1,500,000,000
Line of credit facility	$ 0	$ 0

XML

Financial Instruments - Commercial Paper Program (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Feb. 28, 2013
Short-term Debt [Line Items]
Commercial Paper	$ 0	$ 0
Commercial Paper
Short-term Debt [Line Items]
Capacity of commercial paper program			$ 1,000,000,000

XML

Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Feb. 01, 2023	Dec. 31, 2022	Nov. 08, 2022	Jan. 28, 2013
Debt Instrument [Line Items]
Repayments of long-term debt	$ 1,350	$ 0
Debt, principal amount	6,650			$ 8,000
Senior Notes
Debt Instrument [Line Items]
Debt, purchase price percent due to downgrade of investment grade						101.00%
Senior Notes | 2.000% 2020 senior notes due 2030
Debt Instrument [Line Items]
Debt, principal amount	$ 750			750
Interest rate percentage	2.00%
Senior Notes | 3.000% 2020 senior notes due 2050
Debt Instrument [Line Items]
Debt, principal amount	$ 500			500
Interest rate percentage	3.00%
Senior Notes | 2022 Senior Notes
Debt Instrument [Line Items]
Debt, principal amount					$ 1,350
Debt, unamortized discount					$ 2
Senior Notes | 5.400% Senior Notes Due 2025
Debt Instrument [Line Items]
Debt, principal amount	$ 600			600
Interest rate percentage					5.40%
Senior Notes | 5.600% Senior Notes Due 2032
Debt Instrument [Line Items]
Debt, principal amount	750			750
Interest rate percentage					5.60%
Senior Notes | 3.250% 2013 senior notes due 2023
Debt Instrument [Line Items]
Debt, principal amount	$ 0		$ 1,350	$ 1,350
Interest rate percentage	3.25%

XML

Financial Instruments - Schedule of Long-term Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Feb. 01, 2023	Dec. 31, 2022	Nov. 08, 2022
Debt Instrument [Line Items]
Debt, principal amount	$ 6,650			$ 8,000
Unamortized debt discount / debt issuance costs	(65)			(66)
Current portion of long-term debt	0			1,350
Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)	(26)			(32)
Long-term debt, net of discount and issuance costs	6,559			6,552
Capitalized interest	$ 6	$ 5
Senior Notes | 3.250% 2013 senior notes due 2023
Debt Instrument [Line Items]
Interest rate percentage	3.25%
Debt, principal amount	$ 0		$ 1,350	1,350
Senior Notes | 4.500% 2015 senior notes due 2025
Debt Instrument [Line Items]
Interest rate percentage	4.50%
Debt, principal amount	$ 750			750
Senior Notes | 3.000% 2017 senior notes due 2027
Debt Instrument [Line Items]
Interest rate percentage	3.00%
Debt, principal amount	$ 750			750
Senior Notes | 3.900% 2018 senior notes due 2028
Debt Instrument [Line Items]
Interest rate percentage	3.90%
Debt, principal amount	$ 500			500
Senior Notes | 2.000% 2020 senior notes due 2030
Debt Instrument [Line Items]
Interest rate percentage	2.00%
Debt, principal amount	$ 750			750
Senior Notes | 4.700% 2013 senior notes due 2043
Debt Instrument [Line Items]
Interest rate percentage	4.70%
Debt, principal amount	$ 1,150			1,150
Senior Notes | 3.950% 2017 senior notes due 2047
Debt Instrument [Line Items]
Interest rate percentage	3.95%
Debt, principal amount	$ 500			500
Senior Notes | 4.450% 2018 senior notes due 2048
Debt Instrument [Line Items]
Interest rate percentage	4.45%
Debt, principal amount	$ 400			400
Senior Notes | 3.000% 2020 senior notes due 2050
Debt Instrument [Line Items]
Interest rate percentage	3.00%
Debt, principal amount	$ 500			500
Senior Notes | 5.400% Senior Notes Due 2025
Debt Instrument [Line Items]
Interest rate percentage					5.40%
Debt, principal amount	600			600
Senior Notes | 5.600% Senior Notes Due 2032
Debt Instrument [Line Items]
Interest rate percentage					5.60%
Debt, principal amount	$ 750			$ 750

XML

Financial Instruments - Fair Value of Debt (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Senior Notes | Fair Value, Inputs, Level 2
Debt Instrument [Line Items]
Fair value, debt instrument	$ 6,273	$ 6,108

XML

Financial Instruments - Long-term Debt Maturity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Financial Instruments [Abstract]
2023	$ 0
2024	0
2025	1,350,000,000
2026	0
2027	750,000,000
After 2025	4,550,000,000
Total long-term debt	6,650,000,000		$ 8,000,000,000
Interest expense, net of capitalized interest	63,000,000	$ 53,000,000
Capitalized interest	6,000,000	$ 5,000,000
Line Of Credit For General Corporate Purpose
Line of Credit Facility [Line Items]
Line of credit facility	$ 3,000,000		$ 2,000,000

XML

Financial Instruments - Foreign Exchange Risk (Details)	3 Months Ended
	Mar. 31, 2023
Derivatives Not Designated as Hedging Instruments | Foreign currency forward-exchange contracts
Derivative [Line Items]
Maturity period (in years)	60 days
Derivatives Not Designated as Hedging Instruments | Maximum | Foreign currency forward-exchange contracts
Derivative [Line Items]
Maturity period (in years)	3 years
Derivatives Designated as Hedging Instruments: | Maximum | Foreign exchange derivative instruments
Derivative [Line Items]
Maturity period (in years)	3 years

XML

Financial Instruments - Interest Rate Risk (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Nov. 08, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Cash Received on Hedge	$ 114
Forward-starting interest rate swaps | Derivatives Designated as Hedging Instruments:
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount	$ 50	$ 50
Senior Notes | Forward-starting interest rate swaps | Derivatives Designated as Hedging Instruments:
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount		$ 650
Senior Notes | 3.250% 2013 senior notes due 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate percentage	3.25%
Senior Notes | 4.500% 2015 senior notes due 2025
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate percentage	4.50%
Senior Notes | 5.600% Senior Notes Due 2032
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate percentage			5.60%
Senior Notes | 3.900% 2018 senior notes due 2028
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate percentage	3.90%
Senior Notes | 2.000% 2020 senior notes due 2030
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate percentage	2.00%

XML

Financial Instruments Derivative Notional Amounts (Details) € in Millions, kr in Millions, SFr in Millions, $ in Millions	Mar. 31, 2023 USD ($)	Mar. 31, 2023 EUR (€)	Mar. 31, 2023 DKK (kr)	Mar. 31, 2023 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 DKK (kr)	Dec. 31, 2022 CHF (SFr)
Foreign exchange derivative instruments
Derivative [Line Items]
Derivative notional amount	$ 250	€ 650	kr 600	SFr 25	$ 250	€ 650	kr 600	SFr 25
Derivatives Not Designated as Hedging Instruments | Foreign currency forward-exchange contracts
Derivative [Line Items]
Derivative notional amount	1,716				1,753
Derivatives Designated as Hedging Instruments: | Forward-starting interest rate swaps
Derivative [Line Items]
Derivative notional amount	$ 50				$ 50

XML

Financial Instruments - Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Total derivatives	$ (8)		$ 6
Derivatives Designated as Hedging Instruments:
Derivatives, Fair Value [Line Items]
Total derivatives	(9)		5
Foreign currency forward-exchange contracts | Derivatives Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total derivatives	1		1
Foreign currency forward-exchange contracts	(16)	$ (6)
Foreign currency forward-exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets
Derivatives, Fair Value [Line Items]
Derivative assets	16		22
Foreign currency forward-exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	(15)		(21)
Forward-starting interest rate swap contracts | Derivatives Designated as Hedging Instruments: | Other noncurrent assets
Derivatives, Fair Value [Line Items]
Derivative assets	9		10
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments:
Derivatives, Fair Value [Line Items]
Collateral received	6
Collateral posted	21		21
Additional Collateral, Aggregate Fair Value			8
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other current assets
Derivatives, Fair Value [Line Items]
Derivative assets	11		21
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other current liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	14		9
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other noncurrent assets
Derivatives, Fair Value [Line Items]
Derivative assets	17		19
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other noncurrent liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	6		4
Fixed-to-floating interest rate swap contracts | Derivatives Designated as Hedging Instruments: | Other noncurrent liabilities
Derivatives, Fair Value [Line Items]
Derivative assets	$ (26)		$ (32)

XML

Financial Instruments Cross-currency forward-exchange contracts (Details) - Derivatives Designated as Hedging Instruments: - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Forward-starting interest rate swap contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Unrealized (losses)/gains on derivatives for net investment hedges, net of tax of $(2) and $4 for the three months ended March 31, 2023 and 2022, respectively	$ (1)	$ 26
Foreign exchange derivative instruments
Foreign Currency Fair Value Hedge Derivative [Line Items]
Unrealized (losses)/gains on derivatives for net investment hedges, net of tax of $(2) and $4 for the three months ended March 31, 2023 and 2022, respectively	$ (6)	$ 12

XML

Financial Instruments Cross-currency interest rate swap contracts (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments:
Foreign Currency Fair Value Hedge Derivative [Line Items]
Gain (Loss) on Components Excluded from Assessment of Interest Rate Fair Value Hedge Effectiveness	$ 5	$ 3

XML

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 1,065	$ 1,090
Work-in-process	999	825
Raw materials and supplies	499	430
Inventories	$ 2,563	$ 2,345

XML

Goodwill and Other Intangible Assets - Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Roll Forward]
Beginning Balance	$ 2,746
Adjustments	(1)
Other	(7)	[1]
Ending Balance	2,738
United States (U.S.)
Goodwill [Roll Forward]
Beginning Balance	1,485
Adjustments	0
Other	0	[1]
Ending Balance	1,485
International
Goodwill [Roll Forward]
Beginning Balance	1,261
Adjustments	(1)
Other	(7)	[1]
Ending Balance	$ 1,253

[1] Includes adjustments for foreign currency translation.

XML

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Gross goodwill	$ 3,274		$ 3,282
Accumulated goodwill impairment losses	536		$ 536
Amortization of intangible assets	$ 47	$ 52

XML

Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	$ 2,622	$ 2,650
Finite-lived intangible assets, accumulated amortization	(1,483)	(1,445)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization	1,139	1,205
Total indefinite-lived intangible assets	175	175
Intangible Assets, gross carrying amount	2,797	2,825
Identifiable intangible assets, less accumulated amortization	1,314	1,380
Brands and tradenames
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	91	91
In-process research and development
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	77	77
Product rights
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	7	7
Developed technology rights
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	1,900	1,918
Finite-lived intangible assets, accumulated amortization	(1,006)	(975)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization	894	943
Brands and tradenames
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	390	395
Finite-lived intangible assets, accumulated amortization	(239)	(237)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization	151	158
Other
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	332	337
Finite-lived intangible assets, accumulated amortization	(238)	(233)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization	$ 94	$ 104

XML

Share-Based Payments - Narrative (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options granted, shares | shares	268,008
Share-based compensation, weighted average exercise price (in dollars per share)	$ 162.07
Share-based compensation, Options, weighted average grant date fair value (in dollars per share)	$ 43.56
Share-based compensation, risk free interest rate	3.84%
Share-based compensation, expected dividend rate	0.92%
Share-based compensation, expected volatility rate	28.63%
Share-based compensation, expected term	4 years 2 months 12 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, award vesting period	3 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, award vesting period	3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Graded Vesting Period	3 years
Share-based compensation, granted, shares | shares	262,508
Share-based compensation, weighted average grant date fair value (in dollars per share)	$ 162.08
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, expected volatility rate	31.80%
Share-based compensation, award vesting period	3 years
Share-based compensation, granted, shares | shares	99,626
Share-based compensation, weighted average grant date fair value (in dollars per share)	$ 238.24
Performance Shares | PeerCompanies
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, expected volatility rate	40.90%
Performance Shares | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, target number of units percentage	0.00%
Performance Shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, target number of units percentage	200.00%

XML

Share-Based Payments - Components of Share-Based Compensation Expense (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense—direct	[1]	$ 9	$ 16
Stock options / stock appreciation rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense—direct		1	2
RSUs / DSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense—direct		7	9
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense—direct		$ 1	$ 5

[1] For the three months ended March 31, 2023 and 2022, we capitalized less than $1 million of share-based compensation expense to inventory

XML

Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized	6,000,000,000
Preferred stock, shares authorized	1,000,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	2,300,000,000
December 2021 Share Repurchase Program
Class of Stock [Line Items]
Stock repurchase program, authorized amount		$ 3,500,000,000

XML

Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 4,403	$ 4,544
Other comprehensive (loss)/income, net of tax	(11)	60
Ending balance	4,491	4,658
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(817)	(764)
Other comprehensive (loss)/income, net of tax	(11)	60
Ending balance	(828)	(704)
Derivatives Net Unrealized Gains/ (Losses)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	90	4
Other comprehensive (loss)/income, net of tax	(2)	26
Ending balance	88	30
Net Investment Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	41	5
Other comprehensive (loss)/income, net of tax	(6)	12
Ending balance	35	17
Currency Translation Adjustment Net Unrealized Gain/(Losses)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(944)	(756)
Other comprehensive (loss)/income, net of tax	(7)	21
Ending balance	(951)	(735)
Benefit Plans Actuarial Gains/(Losses)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(4)	(17)
Other comprehensive (loss)/income, net of tax	4	1
Ending balance	$ 0	$ (16)

XML

Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Net income before allocation to noncontrolling interests	$ 551	$ 594
Less: Net loss attributable to noncontrolling interests	(1)	(1)
Net income attributable to Zoetis Inc.	$ 552	$ 595
Denominator
Weighted-average common shares outstanding	463,500,000	472,200,000
Common stock equivalents: stock options, RSUs, PSUs and DSUs	1,100,000	1,900,000
Weighted-average common and potential dilutive shares outstanding	464,600,000	474,100,000
Earnings per share attributable to Zoetis stockholders—basic (in dollars per share)	$ 1.19	$ 1.26
Earnings per share attributable to Zoetis stockholders—diluted (in dollars per share)	$ 1.19	$ 1.26
Antidilutive securities excluded from computation of earnings per share, amount	0	0

XML

Commitments and Contingencies (Details) $ in Millions		1 Months Ended	6 Months Ended
	Sep. 16, 2019 Companies	Apr. 30, 2012	Jun. 30, 2016 USD ($)	Feb. 29, 2012 defendant
Loss Contingencies [Line Items]
Number of multinational companies | Companies	39
Ulianopolis, Brazil
Loss Contingencies [Line Items]
Number of additional defendants				5
Number of claims seeking damages				6
Duration of suspension of lawsuit		1 year
European Commission
Loss Contingencies [Line Items]
Net tax charge | $			$ 35

XML

Segment Information (Details)	3 Months Ended
	Mar. 31, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	2

XML

Segment Information Selected Statement of Income (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenue		$ 2,000	$ 1,986
Cost of sales		588	569
Other (income)/deductions—net		(53)	7
Income before provision for taxes on income	[1]	697	727
Depreciation and amortization	[1],[2]	120	114
Other business activities
Segment Reporting Information [Line Items]
Income before provision for taxes on income		(114)	(98)
Depreciation and amortization	[2]	8	7
Operating Segments
Segment Reporting Information [Line Items]
Income before provision for taxes on income		1,149	1,208
Depreciation and amortization	[2]	40	31
Operating Segments | U.S.
Segment Reporting Information [Line Items]
Revenue		1,005	1,020
Cost of sales		203	185
Gross profit		$ 802	$ 835
Gross margin, percentage		79.80%	81.90%
Operating expenses		$ 188	$ 165
Other (income)/deductions—net		0	0
Income before provision for taxes on income		614	670
Depreciation and amortization	[2]	19	13
Operating Segments | International
Segment Reporting Information [Line Items]
Revenue	[3]	978	948
Cost of sales		291	265
Gross profit		$ 687	$ 683
Gross margin, percentage		70.20%	72.00%
Operating expenses		$ 151	$ 145
Other (income)/deductions—net		1	0
Income before provision for taxes on income		535	538
Depreciation and amortization	[2]	21	18
Corporate
Segment Reporting Information [Line Items]
Income before provision for taxes on income		(208)	(259)
Depreciation and amortization	[2]	32	35
Reconciling Items
Segment Reporting Information [Line Items]
Depreciation and amortization	[2]	0	0
Purchase accounting adjustments		(42)	(40)
Purchase accounting adjustments, Depreciation and Amortization	[2]	39	40
Acquisition-related costs		(1)	(2)
Certain significant items, Earnings	[4]	(22)	0
Certain significant items, Depreciation and Amortization	[2],[4]	0	0
Other unallocated		(65)	(82)
Other Unallocated, Depreciation and Amortization	[2]	$ 1	$ 1

[1] Defined as income before provision for taxes on income.

[2] Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

[3] Revenue denominated in euros was $204 million and $203 million for the three months ended March 31, 2023 and 2022, respectively.

[4] For the three months ended March 31, 2023, primarily consisted of employee termination costs related to organizational structure refinements.For the three months ended March 31, 2022, primarily consisted of product transfer costs offset by other items.

XML

Segment Information Selected Statement of Income Narrative (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenue		$ 2,000	$ 1,986
International | Operating Segments
Segment Reporting Information [Line Items]
Revenue	[1]	978	948
International | Operating Segments | Euro Member Countries, Euro
Segment Reporting Information [Line Items]
Revenue		$ 204	$ 203

[1] Revenue denominated in euros was $204 million and $203 million for the three months ended March 31, 2023 and 2022, respectively.

XML

Label	Element	Value
Dividends Payable	us-gaap_DividendsPayableCurrentAndNoncurrent	$ 153,000,000